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ABSTRACT

The changing landscape of healthcare in the US has created new questions about how to best
provide cost-effective, individualized care. Personalized medicine and more specifically,
pharmacogenomic technology have offered new tools for healthcare providers to use to increase
the efficacy, safety, and cost-effectiveness of care. However, these tools are not being utilized to
their predicted extent in the clinical setting. This study utilized Rogers’ Diffusion of Innovations
theory to investigate some of the reasons why. A multi-question survey, the PI-created,
Pharmacogenomic Adoption Instrument (PAI) ©, was developed to assess the knowledge,
attitudes and experience concerning pharmacogenetic technology in a spectrum of different
healthcare providers and types, and was administered online. This study found both knowledge
and attitude, overall, to be highly correlated to adoption likelihood. Lack of knowledge was the
most frequently cited barrier to adoption. This study also found that the perception of clinical
benefit, the potential for misuse and genetic discrimination, and the ability of providers to
effectively explain, and patients to understand test results, were significant factors in making
decisions about utilizing pharmacogenomic technology. Further, the study found that clinical
setting and the availability of clinical training may affect the perceptions of compatibility and
trialability. These findings suggest that knowledge may be a key requisite, but the most
influential factors on the adoption process are likely related to direct observation of a benefit in
the clinic, including successful patient communication and a positive perception of protections
from misuse of patient data. Therefore, focusing on improvement of the mechanisms for these
processes may help to improve the rate of clinical adoption.
Keywords and phrases: pharmacogenomic, precision medicine, healthcare technology
adoption, genetic discrimination, clinical setting, patient data protection
ix

BARRIERS TO PHARMACOGENOMIC ADOPTION

Chapter I
INTRODUCTION
Background and Significance of the Problem
Historically, the practice of medicine has operated through trial and error. Patients were
prescribed a treatment and if the treatment failed to work or if it caused severe side effects the
patient was prescribed a new treatment. This process continued until a patient was allocated to a
treatment that is both effective and safe for the patient to use. In his 1962 work, the Structure of
Scientific Revolutions, Thomas Kuhn provides a framework for the mechanisms that bring about
revolutionary change and scientific advancement. In what he termed a Paradigm Shift, the
underlying central precepts of a scientific discipline must be re-written to account for a
fundamental shift in the level of scientific understanding. Precision medicine and
pharmacogenomics bring the promise of a new and more precise methodology for diagnosing
and treating disease. As discussed by President Barack Obama, precision medicine offers a
paradigm shift from the historical trial and error model of patient treatment (White House, 2015).
Patient care has the potential to be vastly improved through the utilization of precision medicine
and pharmacogenomic technology. Simple tests are able to identify predispositions and provide
patient treatment with a level of precision and accuracy never before seen in the clinic. Although
there are a number of challenges that need to be overcome, personalized medicine potentially
offers a new paradigm in medicine, one which makes one-size-fits-all prescribing and trial and
error methods obsolete. In the past decade there have been great advances in the development of
genetic tests and great amounts of new correlational research that have identified target genes
and markers that help to diagnose and treat disease based on specific differences in human
genetic variation. Drug, biotechnology, and academic research organizations have been working
1
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to generate more information about specific genes and their relationship to the effectiveness and
safety of many drugs. The side effects of drugs can be dangerous and sometimes potentially
deadly. Drug related deaths, due to adverse events are the sixth leading cause of mortality in the
United States and it is estimated than around 100,000 people in the United States die, annually,
from adverse drug reactions (Ng, Murray, Levy, & Venter, 2009) Based on the successful
implementation of pharmacogenomic technology in clinical experimentation, it has been
theorized that adverse drug reactions could be reduced to a fraction of their current occurrence
(Phillips, Veenstra, Oren, Lee & Sadee; Anderson, 2007). Pharmacogenomic technology can
provide prescribers and supporting healthcare providers the information that describes an
individual’s genetic make-up and how they are likely to react to certain drugs. This information
and its use can greatly reduce adverse events due to drugs and greatly increase the probability of
prescribing a drug in the correct dose that will work effectively for that patient (Crews, 2012).
While the amount of research into genomic biomarkers for disease has been increasing at a
rapid rate and the number of pharmacogenomic tests available has increased significantly, the
adoption of this technology in the clinic has not come close to keeping pace with the rate of
scientific discovery (Hamburg & Collins, 2010). The literature has found that there are many
different barriers that impede the path from the laboratory to the clinic, these range from
potential philosophical ethical issues to a real lack of training and awareness among practitioners
(Leufkens, 2004; Ventola, 2011). In addition to the improvement of the technology itself,
several other factors have greatly increased the accessibility. One of the largest barriers of the
past was the accessibility of information. Though in the past decade, the landscape of
information availability how grown for clinicians, greatly (Marsh and McLeod, 2006). In the
current landscape there are numerous databases and sources of information on genotype
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associations to drugs, as well as information in the prescribing label of many drugs. The
diversity of issues discussed in the literature in different niches, highlights the gap of what is
perceived by healthcare providers to be the greatest barrier in translating pharmacogenomic
technology from the labs into a standard practice in the clinic.
As the healthcare system in the United States continues to evolve, more and more emphasis
has been focused on increasing the efficiency of healthcare delivery. Government health
coverage providers, as well as private insurers have changed the way that they evaluate and
reimburse for the cost of healthcare (Kaiser Family Foundation, 2014). Legislation, such as the
Patient Protection and Affordable care act of 2010 have included measures that hold providers
responsible for controlling the costs, as well as the improving the outcomes of their patients
(Koh, 2010). To cope with the increasing demands, providers have turned to many new
practices and technologies in an effort to reduce the number of return visits, increase the
effectiveness of treatments and ultimately reduce the overall cost, while still increasing the
effectiveness of treating patients. One promising young technology that has been growing for
over a decade, but has yet to be fully utilized to its potential in the clinical setting is
pharmacogenetic testing. Pharmocogenomic testing uses a patient’s genetic composition to
predict how well a drug will work for that patient and whether there are additional safety
concerns, by comparing the individual’s genotype to set of known genotypes that have been
previously been found to have had poor efficacy or adverse events in other patients. A simple,
one-time, blood test can provide a lifetime of predictive medical value in prescribing the safest
and most effective treatments. Up to this point, medicine has, primarily, been practiced through
trial and error. Patients have been prescribed a treatment based on a set of symptoms. Many
diagnostic tests have been developed to confirm a patient’s diagnosis, but not many tests can
3
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predict how well a patient will respond to a specific treatment. One major problem with this
system is that, in some patients, certain drugs will not work as expected. Even worse, other
patients may have dangerous, and sometimes deadly, side effects. These side effects are termed
“adverse drug reactions” and are a huge issue in medicine, as it is currently practiced, both to
patient safety and an issue in the controlling of costs. Patient deaths in the U.S. that occur as a
result from adverse drug events are the nation’s sixth largest cause of mortality (Vora, Trivedi,
Shah, & Tripathi, 2011). Many researchers have hypothesized that it is possible to reduce
adverse drug reactions to a fraction of their current occurrence through the use of
pharmacogenomic technology (Phillips, 2001; Anderson 2007). The paradigm shift to
personalized medicine and pharmacogenomics can offer a novel, and more exact process for
diagnosing and treating illness. Patient care can be made greatly more efficient and precise with
the adoption of personalized medicine and pharmacogenomic technology. Great improvements
have continued to be made in pharmacogenomic testing and in its application in medicine over
the past decade. Many stakeholders have funded a great deal of research to improve the catalog
of genomic markers and their relation to disease.
Though, while development of pharmacogenomic academic research has been progressing
swiftly, the adoption of pharmacogenomic testing and supporting technology has not been
utilized in the clinical setting at the same rapid rate (Hamburg, 2010). This poses the pivotal
question, “why is this, potentially revolutionary, technology not being implemented more widely
in practice?” when it offers the potential to greatly reduce adverse events, save lives and reduce
the financial burden of costs associated with adverse drug reactions?

4
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Problem Statement
In the practice of medicine, a trial and error approach has continuously been used to
diagnose and treat patients. Physicians prescribe drugs, based on a set of symptoms with very
little insight into how these drugs may affect an individual (Crews, 2012). This often leads to
dangerous side effects and adverse events. Drug side effects can be very dangerous and,
sometimes, potentially deadly. Drug related deaths due to adverse events are the sixth leading
cause of mortality in the United States (Vora, Trivedi, Shah, & Tripathi, 2011). It is estimated
than around 100,000 people in the United States die, annually, from adverse drug reactions (Ng,
Murray, Levy, & Venter, 2009). In addition, the prescribed treatments often are only partially
effective or not effective at all. Personalized medicine and pharmacogenomic technology offers
the potential for a simple blood sample to predict how an individual will respond to a given
treatment based on their unique genetic composition. This technology has the potential to offer
healthcare providers a new tool that can help to predict what drugs and doses will work best for
them and which drugs may have dangerous side effects. While this, potentially highly
beneficial, technology is making great strides in the research laboratory, it is not being adopted at
the same rate in the clinic (Hamburg & Collins, of 2010). There are a number of factors that
may contribute to the lack of utilization of this paradigm-changing technology. While a number
of studies have examined the potential for genetic testing as a tool in the clinic there are several
differences between genetic testing and the use of pharmacogenomic technology. While genetic
testing is very highly related to pharmacogenomic technology, it typically looks at a limited
number of genetic markers and lacks the broader privacy and confidentiality concerns of
pharmacogenomics, which examines an individual’s entire genomic sequence (Goldman, 2005).
Even the number of studies that have examined these issues in genetic testing is relatively small.
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However, these studies are the closest insight available in many cases and are highly
generalizable on a number of issues. Though, research that investigates pharmacogenomics,
specifically, is decidedly warranted.
There are a number of theories that have been utilized to predict the nature of decision
making in medical innovations. Three primary frameworks have been used to describe the
mechanisms that have been studied in the process of understanding, accepting and utilizing new
health advancements. They are the Diffusion of Innovation Theory, The Health Belief Model,
and the Theory of Planned Behavior. Yet no one theory provides a comprehensive model that
can predict and describe all of the findings that have been researched thus far in the adoption of
pharmacogenomic technology. This paper will discuss the primary theories that have been
applied to the model of adoption and how various components may relate to one another in an
intra-theoretical model that accounts for a number of factors prevalent in the literature.
The Theory of Diffusion of Innovations may help to explain what factors are impeding
the translation of this advancement in the clinical setting. Roger’s 1967 Diffusion of Innovation
Theory describes the way people, as a group, adopt technology (Rogers, 2010). The theory has
been applied to many technologies that have emerged in and outside healthcare. This theory has
strong applicability and may help to explain how and why the breach exists between the science
and the practice. In a recent survey of US physicians, only 10% of those surveyed indicated that
they felt sufficiently informed about the accessibility of pharmacogenomic technology and how
to appropriately utilize it to aid diagnosis and determine the best course of therapy for patients
(Stanek, Sanders, and Taber 2012). In the process of adoption of new technology there are key
components that catalyze the process. Of these, are the initial attitudes and knowledge of the
potential adopters (Rogers, 2010). When knowledge is insufficient or attitudes toward the
6
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technology are unfavorable adoption of the technology is halted. The next section will propose a
review of the literature that examines barriers to the adoption of pharmacogenomic technology as
perceived by healthcare providers in the frame of Diffusion of Innovation, as well as in the frame
of the Health Belief Model. The Health Belief Model is focused on explaining or predicting
health behaviors by examining the attitudes of the individual. The Health Belief Model relies on
the three core assumptions in an individual’s beliefs that enacting a behavior will have a positive
outcome, that it will help to avoid a negative outcome and that the individual has the requisite
self-efficacy to enact the behavior with confidence. The idea of self-efficacy helps to explain
why knowledge of pharmacogenomic testing is a key factor in the decision-making process
(Bloss, 2011). However the theory lacks the breadth to explain the greater decision making
process and how this mechanism relates to the diffusion of this new technology at the population
level.
Need for this Study
The current literature indicates that there are a number of issues that may affect the adoption
of phamacogenmomic technology as a whole; very few studies have investigated these issues in
limited sub-groups of the healthcare provider population, and often in a narrow context. This
study would be the first to examine a wide breadth of healthcare providers and the cumulative
list of factors that emerges from the literature, at this time. As mid-level providers and physician
extenders take a larger role in the healthcare setting, their feedback becomes increasingly
significant to the question of utilization, overall. The literature also strongly suggests that
addressing these issues could have a large impact on the adoption of pharmacogenomic tests and
thus, greatly improve the quality and cost-effectiveness of care for many. Determining which
specific factors have an effect on the adoption of pharmacogenomic technology and what
7
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knowledge may be lacking could yield strong guidance in planning interventions to improve
knowledge in the clinical setting. As discussed earlier, the research into knowledge in this area
has been specific to a narrow context and often limited to a single group of healthcare providers.
Investigating healthcare providers, as a whole population, would allow differentiation of the
groups in a controlled comparison that could contrast the differences in knowledge among
practitioner type and specialization.
Purpose of the Study
Though the literature has identified many barriers that may be prohibiting the use of
pharmacogenomic testing, only a small number of studies have been done to empirically
investigate these factors and what their relationship is to adoption of this technology in clinical
practice. Studies, such as Condit’s 2003 work, have investigated some factors, but only in one
group of providers, in this case physicians. Healthcare providers such as physician assistants,
nurse practitioners and others have a direct role in patient prescribing and these groups
perceptions of many of the issues discussed have yet to be captured in a an empirical study. This
study would allow for an overall assessment of the composite barriers that emerged from the
present literature. It will also allow for a direct comparison between groups with the questions
standardized to a single instrument, allowing for an “apples to apples” comparison of perception
between provider groups.

8
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Research Questions
Previous scholarly work has examined the different types of clinical providers independently.
This study will aim to compare differences in adoption likelihood and the related factors that
comprise the domains of knowledge and attitude constructs. The theoretical model predicts that
overall knowledge and attitude are core constructs in the path to adoption. Thus, these constructs
were primary factors in research objectives. Since little is known about the role of provider type
or therapeutic specialization of adoption behaviors the four primary questions were addressed:
•

RQ1. Which factors are most strongly related to a resistance in the adoption of
pharmacogenomic technology by healthcare providers in the clinic and do differences
exist among the nominal level variables?
•

RQ1a) Will a relationship exist between likelihood to adopt and demographic
factors (age, gender, years of experience)?

•

RQ1b) Will a significant difference exist in likelihood to adopt among different
therapeutic areas of practice (e.g. oncology, cardiology, primary care)

•

RQ1c) Will a significant difference exist in likelihood to adopt among different
types of practitioners (e.g. MD, NP, PA, etc.)?

•

RQ2. Is there a relationship between knowledge of pharmcogenomic testing and the
likelihood of adoption of pharmaocegenomic testing by healthcare providers in the
clinical setting?

•

RQ3. Is there a relationship between attitudes (will be measured on a continuum from
strongly positive to strongly negative) toward pharmacogenomic technology and the
likelihood of adoption of pharmaocegenomic testing by healthcare providers in the
clinical setting?
9
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•

RQ4. What factors will best predict the probability of adoption of pharmacogenomic
technology in clinical practice?
Research Hypotheses

Based on the research questions that were developed around the emergent gaps in the
literature the following hypotheses address the predicted relationships among the factors
described, respectively.
•

H1a: A significant relationship exist between likelihood to adopt and demographic
factors (such as age and years of experience)
•

H1b : A significant difference will exist in likelihood to adopt among different
therapeutic areas of practice.

•

H1c : A significant difference will exist in likelihood to adopt among different
types of practitioners.

•

H2: A significant relationship will exist between knowledge of pharmcogenomic testing
and the likelihood of adoption.

•

H3: A significant relationship will exist between attitudes toward pharmcogenomic
testing and the likelihood of adoption.

•

H4: A statistically significant regression model will describe the factors that predict
likelihood of adoption.

10
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Chapter II
REVIEW OF RELATED LITERATURE
Introduction
The literature has suggested that there are many different barriers that impede the path from
the laboratory to the clinic. These range from potential philosophical ethical issues, to a lack of
training and awareness among practitioners (Van Delden, 2004; Ventola, 2011). The literature
also shows that there is a great deal of diversity in what different groups of providers consider to
be the primary barrier to adoption. What is more, most of the published works on barriers to
adoption are expert opinions or position papers. Very few studies have been done to empirically
assess what actual healthcare providers perceive to be the largest obstacle in implementing this
technology or what other factors may be deterrents to them. Understanding the underlying
concerns of healthcare providers in this area is a key step to catalyzing the utilization of this
technology to its potential.
Knowledge has been recurrently cited as a factor that may be crucial to the adoption of
pharmacogenomic technology (Bonter, 2011; Ghaddar, Cascorbi, & Zgheib, 2011; Higgs, 2008).
Therefore, a lack of knowledge can logically be viewed as a barrier. One survey in physicians
showed that, indeed, in all of the physicians that were surveyed, the vast majority had a desire to
utilize pharmacogenomic technology to improve the effectiveness of their practice, however only
10% felt that that had an adequate enough understanding of pharmacogenomics to utilize and
understand pharamocogenomic tests in practice (Stanek, 2010). Knowledge of
pharmacogenomic testing is a multi-faceted concept that is made up of many components, some
which have been discussed in the current literature, and others, which have not. The effects of

11
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knowledge may be rooted in awareness issues or could range to issues such as self-efficacy in
understanding and executing test and their results in the clinic (Bonter, 2011). Empirically
determining the role and relationship of pharmacogenomic knowledge in the adoption of
pharmacogenomic technology in a diverse group of healthcare providers is an important step in
developing a model that will help to predict which educational factors would be most important
in training materials. This would be an important first step in catalyzing the adoption and
enabling the utilization of this technology.
Attitude is another category of factors that encompasses a wide variety of issues that may
inhibit the adoption of pharmacogenomic technology by healthcare providers. Attitudes that are
favorable are produced by the benefits or advantages of an innovation, while unfavorable
attitudes come from concerns over possible negative consequences from the utilization of the
innovation (Rogers, 2010). Issues such as concerns over the loss of privacy have been discussed
extensively in the literature as being, potentially, of great concern (Goldman, 2005). A 2003
study of physicians only, found that found that the potential for discrimination was a major
barrier in brining genetic testing into practice (Condit, 2003). The potential for misuse of a
patient’s genetic information could have great consequences for a patient. Negative attitudes
toward pharmacogenomic testing may be related to the potential risk of genetic discrimination,
or that a patient’s genetic data could be used by health insurance providers to discriminate in
insurance screening of patients, based on predispositions that may be detectable in their genetic
code (Rogausch et al, 2006). Though, these types of risks have been well thought-out in and
contemplated in the literature, not much work has been done to quantify the potential for these
consequences in many settings. This may have potentially contributed to a host of fears and
negative attitudes that could have a prohibitive effect in the adoption of pharmacogenomic
12

BARRIERS TO PHARMACOGENOMIC ADOPTION

technology in the clinic. Case-based studies have found that found that the potential for
discrimination was determined to be a major barrier in implementing the technology in practice
in a qualitative manner. However, Quantifying effects from issues such as this, that contribute
to the larger picture attitudes toward adoption in the clinic is an important part of understanding
what actions could be taken to improve the landscape and rate of adoption in the clinical setting.
The process of adopting of new technology in healthcare has been studied in many
applications. When a technology offers significant potential to prevent illness or greatly improve
patient outcomes, it is important to understand what steps need to be taken to initiate the use of a
new technology in the clinic. When an existing technology has been introduced and offers the
potential for a dramatic benefit, but has failed to be utilized to its full potential in the clinic, it is
important to understand what factors are contributing to the failure to launch. Rogers Theory of
Diffusion of Innovation has been used to study this dynamic in many types of technological
advances. Rogers proposes that a core of factors determine the diffusion rate and the subsequent
adoption of new technology by its potential users (Rogers, 2010). The primary factors that
contribute to adoption are; First, the benefits and disadvantages of the technology. As mentioned
the more positive attributes that the target adopting group perceives, the more likely they are to
embrace they technology. Inversely, the more potential negative consequences, the more likely
that group are to be deterred. Second, the channels of communication through which the
innovation will be communicated, affect how the technology is perceived and thus how it will be
received by the target adopting audience. Communication channels include a number of
pathways that information about the innovation can be transmitted. These often determine the
nature of the information that the target audience would receive. These channels of
communication are described by Rogers as “any means by which messages get from one
13

BARRIERS TO PHARMACOGENOMIC ADOPTION

individual to another” (Rogers, 2010). They include scientific publications, peer feedback,
institutional policies, and greater media attention, in addition to many other channels. Third,
time and finally, the macro-context of the social system are also factors that dictate the tone and
breadth of information that is received by potential adopters in a population. The Diffusion of
Innovation Theory posits that this process is then further characterized by demographic. Rodgers
proposes that there are five primary group types of technology adopters. They are, first the
innovators, then the early adopters, then the early majority, followed by the late majority and
finally the laggards. These group labels help to portray different segments of the population in
factions by their readiness to espouse new technology. It is proposed that adoption of new
technology takes happens in a manner described by a typical bell shaped curve. 2.5% of the
population will make up the first group of early adopters, these individuals are termed
innovators. The 70% of the population will wait to gain feedback from individuals that have
already had experience with the innovation before trying it. Finally, laggards make up the small
remaining percentage of late adopters that will hold-out in adoption, until after the vast majority
of the population has utilized and positively accepted the innovation (Rogers, 2010). The theory
describes innovation in a five stage process that depicts contemplation and ultimate reception, by
the target members of the population. These stages begin with knowledge of the innovation,
then progress to persuasion, followed by decision, then implementation, and finally a
confirmation of decision if the resulting implementation yields positive result (Rogers, 2010). In
the knowledge stage exposure to new technology has occurred, but the group or the individual
lacks the requisite knowledge of the technology and must seek and acquire the amount of
knowledge that they perceive as being sufficient to advance to the contemplation and decisionmaking phase of the innovation adoption process. Rogers’ model has been utilized in healthcare
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technology numerous times and the model parallels the innovation to the scientific findings
around the technology. By enacting the model in this setting, the parallel to the channels of
communication and adoption are the transmission and acceptance of novel information in the
scientific community (Berwick, 2003). This view of the dynamic has been used to equate the
adoption of the new technology from science to practice as the acceptance of the advance in
health service in the “community of practice” (Greenhalgh, 2004). While there is a great deal
of other theory that supports the significance of this study, Rogers Theory of Diffusion of
Innovation is the grounding dynamic that integrates the parts into a cohesive whole.
Theoretical Model and Framework:
Diffusion of Innovation Theory in Healthcare Technology
Rogers’ theory of diffusion of innovation is based on the premise that new technology is
received and adopted at different rates by individuals (Rogers, 2010). The theory proposes to
explain the mechanisms for how and why technology spreads through cultures. The theory
proposes that the four main factors determine the diffusion and adoption of new technology.
These factors are the benefits and disadvantages of the technology, the channels of
communication through which the innovation must be communicated, time and the macrocontext of the social system. These channels of communication are described by Rogers as “any
means by which messages get from one individual to another” (Rogers, 2010). Rogers proposes
that the process relies on five groups of technology adopters. These are the innovators, the early
adopters, the early majority, the late majority and the laggards. These group labels describe the
readiness to accept new technology of individuals. The theory proposes that adoption of
technology takes place through the population under a bell shaped curve. The first adoption of
new technology is made by roughly 2.5% of the population; this group is termed the innovators.
15
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The majority of adoption lies, roughly, in the middle 70% of the population, in terms of the
amount of time in adopting new technology, but relies on cues from the innovators and early
adopter group to mitigate risk and perpetuate the technology through communication channels.
The theory also posits that individuals considering change move through five stages in the
acceptance of a new innovation. These stages, in order, are knowledge, persuasion, decision,
implementation, and confirmation. The first stage of an individual’s contemplation is
knowledge. In this stage an individual is exposed to new technology, but lacks knowledge of the
technology and must acquire an amount of knowledge that they perceive as sufficient to
contemplate decision-making of adopting the innovation. The second stage of adoption is the
persuasion stage. In this stage, the individual has now gathered knowledge of the innovation,
and it has piqued the interest of the individual enough that they seek to apply the knowledge. In
the next stage, decision-making, the individual must now critically evaluate the advantages and
disadvantages of the technology and determine its role in their circumstance. If the individual
chooses to accept the innovation, then the technology or idea is implemented. When utilized in
healthcare technology, Roger’s model parallels the innovation to the scientific findings around
the technology, and the channels of communication are equivalent to the transmission and
acceptance of the scientific community (Berwick, 2003).
Rogers’ characteristic S-shaped diffusion curve is often used to represent the relative rate
of diffusion among the population. The curve suggests that the rate of diffusion begins slowly,
then sharply rises once the early adopters have vetted the technology and it has diffused into the
majority, followed by a tapering to a slower rate in the laggards. In populations the ascending
curve corresponds to factors that relate to the adoption process. These are exposure, awareness,
understanding, testing, utilization, and institutionalism. These factors correspond to
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interpersonal factors at the individual level, as well. Those are attitude, knowledge, persuasion,
decision and implementation. All of which would lead up to adoption or a non-adoption
decision.
Greenhalgh equates the adoption of the new technology from science to practice as the
acceptance of the advance in health service in the “community of practice” (Greenhalgh, 2004).
Jenkins et al tested the framework of Roger’s theory in genomic technology adoption in a study
of 1035 family physicians. The study found that knowledge and education of the technology was
a key catalyst in increasing the rate of adoption (Jenkins, 2013).
According to Rodgers, adoption of new technology requires the a vanguard of
“innovators” that while time is a factor in adoption, catalysts such as attitudes, knowledge and
perception of barriers may increase or decrease the rate of adoption in certain groups.
Knowledge of an innovation may be accurate or inaccurate. Often an inaccurate understanding
of an innovation may be based on previously factual information that has since changed with
time. Other times false assumptions may be based on accurate information that is misapplied or
not accurate within the context it is being considered in (Rogers, 2010). Attitudes towards
innovation are more complex, and often have some relationship to knowledge. They are,
typically, a more visceral reaction to an innovation. Favorable attitudes are typically driven by
the benefits or advantages of an innovation and unfavorable attitudes are driven by concerns over
the implementation of the innovation (Rogers, 2010). To catalyze adoption, knowledge needs to
be sufficient and support a favorable attitude. In pharmacogenomic adoption there are many
issues that have existed previously and been discussed, some of which have been addressed in
practical terms and some of which may still be valid concerns. Many issues that were previously
prohibitive have since changed in the landscape; however, perceptions of the previously held
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notions may still persist in the population of healthcare providers. Cost, for example, has long
been discussed as a concern in implementing pharmacogenomic protocols in the clinic. In recent
studies, cost has been cited as a barrier to adoption of this technology. However cost has been
decreasing at a steady rate over the past decade. While this issue represents attitude at face
value, it is exemplary of the idea that attitude is frequently tied to knowledge in the adoption
paradigm.
Relative Advantage
When a provider is engaging the decision to choose to utilize an innovation for a
specified purpose, Roger’s theory posits that it should provide some form of benefit for the task
considered (Rogers, 2010). More precisely, the technology should endorse a relative advantage
over other available options; in this case this would include the technology that is the current
standard of care utilized in the clinical setting. The perception that technologies produce this
advantage, is related to how likely they are to be adopted. Though, what defines an advantage is
specific to the user and not always the same factors in all sub-groups. Lower costs, improved
efficacy, increased safety, reduction of time spent on cases can all be relative advantages to
different users.
Compatibility
Compatibility is another factor that is considered in Roger’s diffusion of innovation
theory. Compatibility describes the extent that the components of the innovation integrate with
the details of the context and setting in which the technology is being considered for use in. To
integrate successfully, the details of the technology must be compatible with the conditions and
needs of the proposed setting for use (Rogers, 2010). If the technology is too cumbersome, or if
it does not fit with constraints of time, resources, or process it becomes far less likely to become
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adopted. In addition to being compatible with the process, and time constraints of the setting,
compatibility may also describe the extent that an innovation is compatible with an individual’s
interpersonal constitution. If an innovation violates the inherent personality characteristic or
core values of a user there may be an individual incompatibility with the technology.
Complexity
In making the decision whether or not to adopt an innovation, the complexity of the
innovation is identified by Rogers as a key concept in decision making (Rogers, 2010). The
complexity of an innovation can be defined as how difficult and how intricate the innovation is
to understand and utilize. The more complex an innovation is to explain and understand, the less
likely it is to be internalized and utilized. Likewise, if the components to the innovation are
complex to execute in practice the innovation is less likely to be adopted. The concept of
complexity also ties back to the concept of relative advantage. Users of a technology need to be
able to understand the advantages and value of utilizing the technology in practice. If the
benefits and advantages are too complex to quantify and explain or understand, then the
technology will not likely be adopted.
Observability
One of the key concepts in Roger’s theory is that of observability. Observability is the
concept that describes how visible use of the innovation is to the potential adopter (Rogers,
2010). Observability describes how accessible the use of the technology is for potential new
users to observe to make assertions about the compatibility and relative advantage of the
technology in practice. Observing the technology in practice gives potential adopters an
opportunity to vicariously gather information used to make determinations and assumptions
about the technology, as well as ask questions about the technology to current users.

19

BARRIERS TO PHARMACOGENOMIC ADOPTION

Observability is a key factor that relates to awareness and the early knowledge. This concept has
been identified as one of the key components in communications channels. Communication
among peers about a new technology and vicarious learning are highly related to the dispersion
of new technology.
Trialability
Another concept in the adoption process is the concept of trialability. Trialability is the
extent that a user can utilize the technology on a test basis (Rogers, 2010). Innovations that
have many smaller components offer new users the opportunity to participate in their utilization
without having to commit to adoption in full. Using smaller components and experiencing the
outcome of an innovation on a smaller scale gives new users the opportunity to test the
technology and validate assumptions about compatibility and relative advantage before adopting
the technology as practice. Technology that has a high buy-in, or rather, that requires a larger
scale commitment offers less trialability, and thus has a higher barrier to adoption, thus must be
perceived better in terms of relative advantage, compatibility, and complexity.
Health Belief Model
In considering the adoption of new medical technology the Health Belief Model (HBM)
is a common theoretical frame that is used to understand the relationship between information
and behavior change. The Health Belief Model is one of the most commonly utilized theories in
health education and promotion (Glanz, Rimer & Lewis). Dating back to the 1950’s the original
incarnation of the HBM was developed to help determine why new health screening programs
were not being successfully adopted (Hochbaum, 1958). The HBM is driven by the underlying
concept that health behavior is determined by a number of factors that create an individual’s
perception of disease and how they relate these perceptions to the possibility of developing the
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disease and strategies for prevention and treatment (Hochbaum, 1958). Many components of the
health belief model are used to predict how information may initiate action and what information
is needed by the receiver to initiate the utilization of new technology. Though the Health Belief
Model is most frequently used to predict the behavior of patients in utilizing information and
technology for health intervention, in some cases it has also been used to help to predict the
behavior of healthcare providers in utilizing new technology as a channel to make the innovation
available to the patient (Bloss, 2011). A key component of the health belief model is called a
“cue to action”, this is an information providing event that causes the receiver of that information
to consider the potential value of the innovation or interventional technology that could cause the
receiver of that information to make decisions about the future adoption of behaviors regarding
the technology (Hochbaum, 1958). In genomics the illness of a family member is often a cue to
seek information about a disease that may have an impact on the individual (Graham, 2001).
Maternal breast cancer and BRCA gene variants are a great example of this. In this case, the
beliefs of the healthcare provider regarding the value of genomic testing in treating and
preventing disease would be related to the amount of information acquired, in conjunction, with
the perception of risks associated with the innovation and attitudes related to the individual,
cultural context and local or institutional practices that reflect the beliefs about the innovation.
In this case, the healthcare provider must first acquire the information needed to fully understand
and provide the technology to patients they may benefit. While this type of macro relationship
may be described by Roger’s Diffusion of Innovation Theory, integrating components from the
Health Belief Model also allows for a finer discernment of the concepts that drive decision
making at the individual level. While the Diffusion of Innovation Model focuses on
communication channels in the larger context, and the available knowledge of the collective
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group, the Health Belief Model allow an assessment from a lens focused more toward individual
compatibility with adoption of the technology and the execution of the actionable behaviors
associated (Carpenter, 2010). One of the key constructs of the Health Belief Model, as it is
applied in this instance is the concept of Coping Style, this aspect describes how and individual
deals with information that carries potential predictive values of negative outcomes (Ogden,
2012). When individuals encounter this type of information some seek further information to
make sense of and contextualize the new information that they have acquired. Other individuals
may have personality types that tend to avoid the serious new information, or downplay its
significance. It is anticipated that those who are likely to seek new information would be more
likely to adopt new technology, such as pharmacogenomic testing. Locus of Control and SelfEfficacy are two highly related constructs considered by the Health Belief model that may have
significant predictive value when considered in the context of adopting pharmacogenomic
technology (Ogden, 2012). Locus of Control is the extent to which individuals perceive to have
control over their own decisions and the extent to which outcomes are related to those decisions.
In the Health Belief model an individual needs to perceive that their decisions are likely have an
impact on the outcome to become inclined to make the decision to adopt pharmacogenomic
technology (Ogden, 2012). Therefore, it is anticipated that those individuals that have had
experiences in which they have observed efficacy in genetic testing or other similar related
predictive models will be more likely to have a disposition that favors the use of
pharmacogenomic technology in future clinical settings. Self-efficacy is the internalized
component of Locus of Control. While Locus of Control describes an individual’s overall
perception of their ability to impact outcomes, Self-Efficacy is their own innate confidence in
their own abilities to effectively impact outcomes. Self-efficacy is a highly important construct
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that is directly related to one’s own perception of knowledge. Typically, high levels of
knowledge and experience with content or subject matter correlate to higher levels of selfefficacy. That is, the more an individual has learned and practiced a behavior, the more likely
they are to believe that they possess the requisite abilities to understand and execute related skills
in a future context. Self-efficacy is a concept that is frequently studied in health technology
adoption models that require an individual to process complex and/or a large volume of
information. There is a great deal of complexity in the information considered for the adoption
of pharmacogenomic testing. Therefore, it is expected that greater levels of prior exposure to
genomic technology and greater levels of knowledge will correlate to higher levels of selfefficacy and thus a higher likelihood of adoption of pharmacogenomic technology in clinical
practice.

Barriers to adoption of pharmacogenomic technology
The successful adoption of pharmacogenomic technology, in clinical practice, requires
overcoming of the barriers to utilization that exist in the clinic. The term barrier is often used to
describe a number of issues, concerns or obstacles that impede adoption of this technology.
Sometimes these barriers are tangible in nature and may need to be addressed with tangible
solutions. In the hypothetical case that cost of testing was a tangible barrier to adoption, funding
would need to be allocated to ameliorate the lack of available funds needed. Other times, what
are deemed to be barriers are the perceptions of the target adopter, which may be inaccurate or
not up to date with current realities of the technology. In the case that a healthcare provider
perceives cost to be a barrier, the perception of cost must be compared to the current
expectations of cost and available funding to see if the perception is accurate. Only then can a
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determination be made on what the solution is. If the perception of cost is inaccurate or
outdated, then the potential solution would be to increase awareness of the current cost of
technology. To empirically identify what these barriers actually are and determine if they differ
by therapeutic specialization, geographic location, or other factors, an assessment of what the
primary barriers are perceived to be needs to exist. Though, no U.S. study has done this in all
healthcare providers, a 2011 study surveyed oncologists, cardiologists and family physicians in
Canada to determine what the greatest perceived barriers were to the adoption of this technology
(Bonter, Desjardins, Currier, Pun, & Ashbury, 2011)

The study found that the primary

perceived barriers to the adoption of pharmacogenomic technology and the practice of
personalized medicine were; the lack of clinical guidelines (60% reported to be one of the “main
barriers”), limited provider knowledge and awareness (57% reported to be one of the “main
barriers”), lack of evidence-based clinical information (53% reported to be one of the “main
barriers”), cost of tests prohibitive (48% reported to be one of the “main barriers”) These
findings are in agreement with what Gurwitz proposes are the primary barriers to
pharmacogenomics program development in the European Union (Gurwitz, 2009). Gurwitz
cited health professional unfamiliarity, unclear cost-effectiveness, and an unclear regulatory
framework as being some of the primary challenges of translating research findings into clinical
practice (Gurwitz, 2009). Anderson et al, provide an Australian perspective, which cites that
perception of a need for privacy and confidentiality and a lack of formal guidelines are the
primary issues, locally (Anderson, 2012). In agreement, with this notion, McKinnon and
colleagues propose that one of the biggest challenges to clinical providers is developing
consistent clinical protocols that utilize genomic test results to guide clinical practice
(McKinnon, Ward, & Sorich, 2007). McKinnon’s critical analysis of barriers identified cost-
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effectiveness of tests, ethical concerns over the use of DNA, and a gap in technical knowledge of
the subject matter. A 2003 study by Condit et al looked at the some of the perceived barriers in
the general population and aimed to assess the understanding of individuals, as it related to this
barrier. The study found that found that the potential for discrimination was a major barrier in
implementing the technology in practice (Condit, Templeton, Bates, Bevan, & Harris, 2003).
Indeed, privacy concerns are one of the thematically discussed concerns in the attitudes toward
adoption. The sensitive nature of genetic information and the potential impact that it could have
on an individual is a major concern in the literature, which has been brought up, philosophically,
by many authors. The Clinical Pharmacogenomics Implementation Consortium (CPIC)
conducted two survey studies to assess unmet needs in phamacogenomic testing (Relling &
Klein, 2011). The focus of this study related primarily to scientific issues in translating scientific
findings, specifically, into applications. While the studies primarily dealt with scientific issues
that limited testing capabilities, the surveys also had some findings had implications about the
suggested challenges to the translation of pharmacogenetics in the clinical setting. One of the
findings was that there was an absence of guidelines of the processes to interpret genotype
information and a clear path on how to translate that genetic information into clinical practice
applications. This finding was coherent with the findings of others, such as Bonter in which a
clear framework was perceived as a barrier to the adoption. The study also found that providers
may be resistant to considering pharmacogenetic information when making practice decisions.
While the specific details of why were not defined as clearly as in other studies, the themes of
cost and reimbursement were re-iterated in these findings (Relling & Klein, 2011).
Haga and colleagues also performed a survey study in 597 primary care physicians in
2012. The study found that primary care physicians aim to function as a primary point of
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delivery of pharmacogenomic technology, but that they recognize that a deficit of sufficient
knowledge and experience is a limiting factor (Haga, 2012). The findings of the study suggest
that educational curricula, training and resources have failed to progress, and do not contain an
adequate amount of information to satisfy the needs of primary care physicians in prescribing
pharmacogenomic testing. This further highlights the need for the development of effective tools
for guiding healthcare provider decisions utilizing pharmacogenomics in clinical practice.
There are many factors that can be categorized as “barriers” to the adoption of
pharmacogenomic technology in the context of Rogers’ Diffusion of Innovation Theory. In most
of these factors, there is in interaction between knowledge and attitudes. This paper will attempt
to distinguish the nature of the relationship between these factors, as it is described in the
literature, to the extent that it is.
Knowledge and attitudes towards cost as a barrier
Cost, at one time, was initially a prohibitive factor in the early development of
pharmacogenomic technology. Ginsburg and colleagues addressed the question of cost
effectiveness of pharmacogenomic technology in their 2005 position paper (Ginsburg,
Konstance, Allsbrook, & Schulman, 2005). At the time, the question of cost had been subject to
many conditions. While long run costs showed a favorable ratio, the immediate up front expense
had been identified as a large consideration in implications for the development of
pharmacogenomic technology into routine clinical practice. Since that time, the costs of use
have fallen dramatically. However, cost may still persist as a perceived barrier in attitudes of
healthcare providers. It is important that the most up to date understanding of cost effectiveness
be understood by the target users of the technology. In actuality, the utilization of patient
genotypes has the potential to save healthcare payers the costs of longer term hospitalizations
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(Crews, Hicks, Pui, Relling, & Evans, 2012). The term ‘$1,000 genome’ has been a long time
target for the genomics industry. This term has been symbolic of the potential for DNAsequencing capability to become so affordable that any individual could afford the once-in-alifetime investment to obtain their own personal genome sequence for future physicians’
reference (Church, 2006). In January 2014 the biotechnology company, Illumina introduced the
HiSeq X Ten Sequencer which is the first product able to sequence an individual’s genome for
under $1000 with a sequencing depth of 30x or greater. This huge advancement in the platform
scientific technology that drives genome sequencing was a large milestone in cost reduction of
pharmacogenomic technology that has long been a goal in the industry. No studies have yet
evaluated the topic of cost effectiveness in the post $1000 genome era. Due to this very recent
development, cost as a barrier needs further investigation within this cost paradigm.
A 2010 paper suggested that there is complexity in weighing the cost benefit of
pharmacogenomic technology by healthcare payers, because of the different efficacy associated
with different markers (McKinnon, 2010). Cost-effectiveness is often shown for specific
diagnostic test, but no comprehensive framework yet exists for evaluating the technology,
overall. Ventola’s 2011 paper discusses cost as a concern, further, framed in the structure of
reimbursement (Ventola, 2011). Though many payers do cover genomic tests, others have
complex policies that may be generic to all diagnostic tests and don’t always cover the specific
circumstances of the patient. Ventola’s study found that some insurers had cited that they had
been reluctant to cover pharmacogenomic tests, because the cost-effectiveness of the test was in
question. However, even in cases where the cost-effectiveness of a test was clearly
demonstrated, that this factor was not the influencing factor for payers to agree to cover the costs
(Ventola, 2011). Ventola’s research found that, instead, the two most significant factors to
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payers in deciding to cover the cost of the test were clear evidence of clinical utility and
endorsement by professional guidelines. Deverka,Vernon, and McLeod analyze cost
comparative cost-effectiveness from a more holistic model (Deverka,Vernon, & McLeod, 2010).
They’re analysis suggests that pharmacogenomics has the long-term potential to deliver immense
cost savings to the healthcare delivery system. However, there exists somewhat of a catch 22.
The net effect of cost savings is cumulative and as more prescribers and physicians participate in
genomic profiling and screening the more data is compiled and the more efficiently healthcare
providers can prescribe. Therefore, current evidence suggests that not only is there a net cost
savings to patients and providers currently, but as the technology continues to be utilized the
cost-effect is compounded and will drive greater efficiency into the current healthcare cost model
(Deverka,Vernon, & McLeod, 2010). Despite the fact that cost has continued to decrease,
historically cost continues to persist as a concern among clinical providers. It is unclear, at the
current time, what the effect of the most recent technology cost improvements have had or will
have on the perception of cost as a barrier.
Clinician attitudes toward pharmacogenomic technology
Clinician attitudes towards pharmacogenomics encompass a broad array of social, ethical,
and emotional considerations that affect how individual practitioners feel toward the use of this
innovation. One of the key catalysts to the adoption healthcare technology is the attitudes of the
potential adopters. Indeed, many studies, such as the work of Greenhalgh conceives, in
agreement with Rodgers, that adopter attitude is key component in the stages of adoption of
innovation in healthcare (Greenhalgh, 2004). Though there is a great deal of literature that
philosophically examines the potential ethical and social concerns of utilizing
pharmacogenomics in the clinic, there have been few empirical studies that examine the attitudes
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of healthcare providers in this regard. There has, yet, been no study in the U.S. that has
examined the attitudes toward pharmacogenomics of all healthcare providers as a group. In the
U.S., a few research studies have looked at the attitudes of pharmacists. (Anderson et al, 2012)
A 2012 study, of over 700 pharmacists utilized an online survey to assess the knowledge,
attitudes and education pertaining to pharmacogenetic technology and testing (Roederer, Van
Riper, Valgus, Knafl, & McLeod, 2012). The study found that over 90% of participating
pharmacists had a desire to acquire more knowledge of pharmacogenetics and genomic testing.
The study found that length of time in clinical practice was a factor in the preference of delivery
methods for educational and training materials. Pharmacy practictioners with 10 years of
experience or less were more likely prefer online web delivered training or education. The study
provided further insight into the baseline education and training composition of this group. The
majority of pharmacists were found to have limited formal education or continued education
training in pharmacogenetics. The survey also found that the ability of this group to self-assess
their knowledge of the subject accurately was high. It also empirically supported the theme that
pharmacists were more likely to have a positive attitude about clinical pharmacogenetic testing if
they had received prior education in pharmacogenetics (Roederer, Van Riper, Valgus, Knafl., &
McLeod, 2012).
A 2011 study examined themes in open-ended qualitative responses from over 2000
participants, primarily pharmacists and nurses (Dodson & Van Riper, 2011). This study
highlights many of the previous themes of various pieces of literature and had some new
concepts emerge. The study was the first to capture information on pharmacogenomic attitudes
from a mixed group of healthcare providers. The study captured the perceptions of pharmacists
and nurses in North Carolina. The study collected participants’ thoughts and concerns on
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genomic testing and found five major themes. The themes were negative concerns for the
application of genetic testing, lack of successful integration into standard of care, accessibility of
genetic testing, potential harm, and optimism. A negative perception towards the application of
genomics in the clinic is a common concern in papers philosophically examining ethical
considerations of pharmacogenomic technology in clinical practice. This study also employed
an open-ended question, which received 184 responses. The publication article only briefly
discusses the closed-ended questions, but goes into great depth regarding the open-ended
question response and the thematic analysis that was done on this data. One of the themes that
emerged from nurses was a concern for patient education. That is how could patients be
effectively educated about this technology in the short time that providers have to provide care?
Replies included a highlighting of the need for genetic counseling in some situations. This
theme in the thematic analysis demonstrated the clinical perception that patient acceptance would
be reliant on patient education and this need has been only sparsely addressed (Dodson &
VanRiper, 2011).
Knowledge and attitudes related to misuse and privacy concerns
One of the most controversial issues in the utilization of pharmocogenomic technology is
the protection of patient’s privacy and the potential for future discrimination based on genetic
information. Patient genetic information is a very permanent and potentially significant piece of
private data, which has implications that heighten the privacy concerns of both patients and
providers. Ultimately, the translation of pharmacogenetic technology into routine clinical
practice will depend upon the patients’ and healthcare providers’ acceptance of the use of
pharmacogenomic tests in the clinic and a trust that the use of these tests is safe with regards to
patient confidentiality and disclosure (Rogausch et al, 2006). Pharmacogemonics offers unique
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challenges, as the nature of genomic data is broad in scope and offers a greater risk of loss of
confidentiality, when compared to genetic testing (Goldman, 2005). The potential for misuse of
this information could have great consequences for a patient. One of the largest concerns is the
risk of genetic discrimination, or that a patient’s genetic data may be used by a health insurance
provider to discriminate in insuring patients, based on predispositions that may show in their
genetic code. However, genetic data is for this reason, heavily encrypted and held to rigorous
confidentiality standards. Though, the changing nature of informatics and data management
technology blurs the actual probabilities of security risks of a breach of these protections. The
privacy protection landscape varies by local jurisdiction (Tene, 2011). Within the US, privacy
protection and data handling laws regarding genetic information have varied. The perceptions
relating to a risk of loss of confidentiality have been a leading concern in the negative attitudes
towards pharmacogenomics. However, there have been many measures taken to ameliorate the
risk in these potential of these scenarios. Further, the US Congress passed a legal act in 2008,
called the Genetic Information Non-discrimination Act of 2008 to legally prohibit health plans
and insurers from denying coverage or charging higher premiums to individuals based on genetic
predisposition (NHGRI, 2008).
In a 2011 study of 59 third year medical students from the American University of Beirut
it was found that privacy was a leading concern in the use of genetic testing for developing
treatment plans. The concern for confidentiality of patient data was high there was an
overwhelming concern over genetic discrimination and its effect on insurability (Zgheib, 2011).
This study highlighted medical students’ perceptions of the role of pharmacogenetic testing
information and describe the attitudes of medical students considering pharmacogenetic tests in a
clinical setting. The study utilized several case scenarios and a questionnaire that measured
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several concerns in potential genomic testing scenarios in various therapeutics diseases. The
study found that in patients that were found to have negative markers for certain diseases, the
sensitive nature of a genomic prognosis induced several ethical issues related to privacy. Many
students were found to have concerns initiating a treatment utilizing the pharmacogenomic
diagnosis as they were uncertain of the implications of potential genomic discrimination and
issues with future insurability of these hypothetical patients. Though the legal, regulatory and
cultural landscape of Beirut limits the generalizability of these findings as applied to the
application of ethical concerns in the US, the study reflects the theme that is common in the
philosophical literature, verified empirically as a major concern in a population of healthcare
providers.
Clinician knowledge of pharmacogenomic technology
Knowledge has been repeatedly identified as a key barrier in the adoption of
pharmacogenomic technology by clinicians. While Bonter’s study identified a lack of
knowledge as being one of the primary perceived barriers to clinician adoption (Bonter,
Desjardins, Currier, Pun, & Ashbury, 2011), other studies have focused solely on knowledge as a
prerequisite to the utilization pharmacogenomic technology in the clinical setting. Qualitative
studies found that if healthcare providers lack the pre-requisite knowledge of
pharmacogenomics, they will be far less likely to have a favorable attitude toward utilizing
pharmacogenomic tests in the clinic (Ghaddar, Cascorbi, & Zgheib, 2011). Higgs and colleagues
2008 study examined the knowledge of pharmacogenomics in 19 British medical students
(Higgs, 2008). Though the survey was in medical students and in Britain, some of the content is
relevant to the dimension of knowledge in physicians.
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In a cross-sectional study by Stanek and colleagues, investigators measured the baseline
levels of US physicians' knowledge of pharmacogenomics and their respective utilization of
pharmacogenomic technology in clinical practice. (Stanek, Sanders, Taber 2012)

97.6% of

participants indicated that they had some knowledge of pharmacogenomics, but only 10.3% felt
that they had an understanding of pharmacogenomic technology that was adequate enough to
utilize it in the clinic. The incidence of utilization of genetic tests for the purpose of treatment
planning was found to be relatively low with only 12.9% of physicians utilizing a
pharmacogenomic test in the 6 months prior to the survey. (Stanek, Sanders, Taber 2012)
Looking forward 26.4% of physicians indicated that they planned to order a pharmacogenomic
test in the next 6 months. Those who scored high in measures of early adopting behaviors of
pharmacogenomics were more likely to have received some prior or education training in
pharmacogenomics. Only about 29.0% of physicians had ever received any prior professional
or academic training in pharmacogenomics (Stanek, Sanders, Taber 2012) These findings
further highlight the indication that knowledge and education are important factors in the
adoption of pharmacogenomic technology by physicians in the clinic.
Knowledge of the where healthcare providers can find clear, curated, peer-reviewed
guidelines that translate pharmacogenomic test results into clinical prescribing protocols for
treatment regimens is thematic in the literature that explores knowledge (Relling & Klein, 2011).
As mentioned, Bonter and colleagues found this lack of knowledge to be one of the primary
barriers to adoption. The CPIC study found that there was an absence of guidelines of the
interpretation of genotype information that there was not a clear path on how to translate that
genetic information into clinical practice applications. This finding is thematic in studies that
examined knowledge as it relates to attitude. The knowledge of clear framework for tests and
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treatments was continually perceived as a major barrier to adoption. The study also found that
providers may be resistant to considering pharmacogenetic information when making practice
decisions (Relling & Klein, 2011). This, again, underscores how the lack of guidelines presents
in the barrier of clinical uncertainty.
Therapeutic specialization
There is some evidence that differences exist in knowledge and attitudes by clinical
therapeutic area of practice. There is some literature that discusses the differences in adoption by
clinical therapeutic field. The specific nature of some disease, as well as the unique nuances of
some areas of care, present the possibility that there are differences in the barriers to adoption in
various medical specializations. This notion has been presented in the literature philosophically,
in a number of forms; however, it has yet to be explored empirically. Ventola’s 2011 paper,
analyzes industry differences and the potential effects on adoption among practitioners of
oncology, cardiology, psychiatry, and infectious disease (Ventola, 2011). The number of
genomic diagnostic tests that were available in each field was a product of the environment
within that field to pharmacogenomic adoption. Oncology has historically been at the vanguard
of pharmacogenomic discovery and translation to practical application (Squassina, 2010).
Swen hypothesizes that there may be some specializations that favor the adoption of
pharmacogenomic technology more highly than others (Swen, 2012). The paper proposes that
generalist providers may lack the technical knowledge and experience to effectively utilize
pharmacogenomic tests in the clinic. He proposes that specializations such as oncology that
routinely necessitate the utilization of DNA markers may be better equipped and therefore more
likely to adopt this technology in full, in clinical utilization. Additionally, the paper proposes
that family physicians and oncologists differ greatly in the composition of the routine tests that
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they utilize in practice. Most therapeutics are based on complex mechanism of action in which
multiple genes effect a number of pathways, which increases the complexity of models around
genomic testing. Pharmacogenetic tests available in oncology, however, are more likely to be
related to a single drug and a single genetic variation (Swen, 2012). Thus, previous experience
and a simpler model may offer a predisposition in the oncology setting. This may help to explain
the notion that providers in oncology have greater knowledge and more favorable attitudes
toward the adoption of pharmacogenomic technology in the clinic that is thematic in the
literature.
Haga looked, specifically, at primary care providers to see if there were barriers in this
precise population that limit their ability to utilize this technology in practice (Haga, 2012). This
study also found that knowledge was insufficient in primary care providers and that limited
training opportunities and limited access to information portals made primary care physicians
less confident in utilizing this technology to guide a diagnosis. This study suggests that primary
care providers face challenges that are unique to their circumstance. As Swen noted earlier these
issues may be related to previous experience, a lack of knowledge and inadequate access to
information. Haga notes, though, that primary care providers have a desire to provide
pharmacogenomic testing and utilize the results for clinical guidance, but these mentioned
“barriers” are preventative.
Based on the factors described in the literature a theoretical model was devised for the
study that centered on Rogers Diffusion of Innovations Theory, taking into account the domains
of knowledge and attitude and considering the specific factors described in the empirical and
philosophical literature. The study framework described the main attitude factors to be measured
as Diagnostic/Clinical Value; Cost Effectiveness; Increased Drug Safety; Impact on Quality of
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Healthcare; Potential for Misuse of Genetic Data; Genetic Discrimination; Ability of Providers to
explain and Patients to Understand Tests. The attitude factors to be measured included
Comprehension of Basic Genetics and Pharmacology; Experience in the Clinic; Literature Read;
Training; and Education.
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Figure 1: Initial Theoretical Framework for Study. The above figure illustrates the theoretical
framework for the study design, incorporating the factors from literature review into Rogers’
Diffusion of Innovations Theory.
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Chapter III
RESEARCH METHODS
Research Design
The study employed a primary cross-sectional, correlation design with exploratory measures
to further characterize the perceived barriers in pharmacogenomic adoption. Some open-ended
questions and clarification questions were employed to capture previously undiscovered
qualitative concepts. The correlational design allows for relationships to be described between
predictor variables and outcome factors (Portney and Watkins, 2008). The exploratory
components of the study tool will allow for characterization of perceived barriers through the use
of qualitative methods, such as open-ended questions and thematic analysis. Thematic analysis
methods can often help a researcher to discover new concepts that have not been previously
identified (Maxwell, 2013). Since, some of the provider groups studied had been studied,
individually, previously, there was a basis for measuring a number of factors that related to
constructs in those groups clinical settings, with the caveat that this overall population was
unique and that previous observations may not hold true in a group to group comparison of
different providers. This design component is elucidated further in the tools section, in which is
discussed how factors were operationalized in an among groups comparison. The study design
and plan was submitted to the Seton Hall University and Institutional Review Board approval
was obtained (Appendix A). Acknowledgement and authorization to conduct the study was
provided by PRA Health Sciences (Appendix D).
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Setting
After receiving IRB approval (Appendix A), this study was implemented via an online
survey data collection service, Survey Monkey and was open to healthcare providers nationally.
Though the initial link was released only to members of the Seton Hall School of Health and
Medical Sciences, this group was encouraged to further recruit participants, if desired, through
the use on chain-link or “snowball” sample referrals. The study utilized a form of nonprobability sampling called chain-referral sampling, also known as snowball sampling. Snowball
sampling offers researchers the ability to utilize a target demographic to find other members
within the same target parameters through referral by the initial recipients (Goodman, 1961).
This sampling technique utilizes the same theoretical structure as social network media, offering
the potential to ultimately, possibly access the entire population, given sufficient time
(Explorable.com, 2009). The study utilized the base population of Seton Hall University School
of Health and Medical Sciences e-mail list to distribute the PI-created PAI© link to the initial
subjects. The Letter of Solicitation accompanying the PI-created PAI© incorporated language
that encourages recipients to forward the link to any friends, colleagues, or associates that they
think may fit the described criteria for inclusion and exclusion (Appendix E). Since the
recipients may have forwarded the link to any number of secondary recipients and those
secondary recipients were then able to forward it to any number of tertiary recipients, this is
termed exponential snowball sampling. Since the respondents had to self-qualify according to
the inclusion and exclusion criteria provided for at the beginning of the survey, for the inclusion
and exclusion criteria, the sampling method was also exponential discriminative snowball
sampling (Explorable.com, 2009).
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Sample
The sample was obtained through chain link referral sampling as described in the
methods section. The initial invitation and link were sent out to the distribution list of the School
of Health and Medical Sciences at Seton Hall University after permission was granted (Appendix
C). Subjects were self-identified as healthcare providers that were involved in patient
medication and/or pharmacology decision-making related practice within the United States that
responded to the anonymous pharmacogenomics survey link, sent via e-mail. Although the
sample was national in scope, the majority of respondents were from the metropolitan NJ, NY
and PA area, because non-purposive (snowball) sampling is being used, it becomes impossible to
merely limit the respondent pool to a particular region of the United States. Thus the
generalizability of these results is representative of this Northeast region. Based on the methods
described by Bartlett on survey study sample size determination, about 221 responses were
expected to be required to accurately represent the target population (Bartlett, Kotrlik, and
Higgins, 2001). This number was based on the PI-created PAI© tool attributes and a 3% margin
of error for categorical data and a 5% margin of error for ordinal level data. It was also based on
the assumption of a population size estimate of about 1,000,000 healthcare providers and a
confidence level of 90%. To achieve this number, assuming a 20% response rate, about 1105
potential subjects were estimated to have needed to receive the PI-created PAI© . Furthermore,
a power analysis was conducted to control for the possibility of failing to reject a false null
hypothesis, or committing a Type II error. This was preventable by achieving a minimum power
of at least 0.8 (Portney and Watkins, 2008). The statistical program, G-power 3.1, (Faul,
Erdfelder, Lang & Buchner, 2007) was utilized to calculate the appropriate sample size for
sufficient power based on the parameters of the PI-created PAI© instrument (Appendix B). This
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tool was used to qualify the estimate of n=221 from above to assure that this sample size would
meet the statistical requirements for all tests projected to be performed. An f2 was utilized to
determine the appropriate minimum sample size required to test for significance, which is
calculated by R2/ (1 -R2). In G-power, a multiple regression omnibus (R2 deviation from zero)
test was selected for a priori power calculations. A small effect size estimate f2 of .08 was
selected. Using the significance level of 0.05, in order to detect the small effect size of 0.08, the
minimum sample size was determined to be 213 with up to 10 predictors with an actual power of
.802. Given these results, the original estimate of n=221, based on survey methodology
conventions, it was very likely that an effect will be detected, if one exists.
Tools and Instruments – Pharmacogenomic Adoption Instrument
The literature showed that there was not one singular instrument that was equipped to
measure all of the factors included in the theoretical framework, in all of the provider groups
investigated in this study. There, in fact, were only a few survey tools that have measured
perspectives on pharmacogenomics and its use in the clinic. Only one has directly measured
barriers to adoption, this was done only in physicians in Canada (Bonter, Desjardins, Currier,
Pun, & Ashbury, 2011) Though none of few the survey instruments that captured perspectives
on pharmacogenomics, precisely measured healthcare providers perceived barriers to adoption in
the clinic, each of those studies offered some insights and helped to, collectively, offer topical
themes. Although, no one instrument captured all of the emergent themes in the literature, each
survey tool, provided a strong empirical demonstration of its abilities in exploring some of the
thematic concepts of interest that emerged.
In Bonter and colleagues 2011 study, the research team aimed to measure barriers to
adoption of personalized medicine technology in clinical practice, including pharmacogenomic
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technology. The study utilized a survey tool that was provided to Canadian oncologists,
cardiologists, and family physicians. The survey instrument questions captured demographic
information, training, practice, knowledge and education information about pharmacogenomics
and personalized medicine. It measured their perception of its use practice in their area of
specialization, and the benefits and barriers to its adoption. The survey had a response rate of
about 8.3% and responses were obtained online, by mail or by fax. The survey has not been
utilized in U.S. populations or populations other than Canadian physicians. The draft of this
survey was reviewed by an expert panel of 11 physicians and modified to include their feedback.
The design of the survey was built around adoption of innovation in clinical practice and
diffusion of innovations framework was the underlying theoretical model for the structure.
Barriers were considered in the context of knowledge and attitudes in the practice of
personalized medicine, pharmacogenomic testing to measure perceptions of relative advantages,
compatibility, ease of implementation and institutional responses to adoption of
pharmacogenomic technology (Bonter, Desjardins, Currier, Pun, & Ashbury, 2011) Bonter’s
study is one of the few to explore the question of specialization as a factor, which was
approached several times philosophically, but only very few times measured empirically.
Though Bonter only captured three areas of therapeutic specialization, these three showed some
differences in key areas (Bonter, Desjardins, Currier, Pun, & Ashbury, 2011) One item of
interest that provided empirical evidence on a question previously philosophically posed in the
literature was whether knowledge differed significantly by area of specialization. Bonter’s
survey measured factors that related to probability of adopting and utilizing genomic tests. It
found that those in the specialty of oncology were more likely (27% χ2 p=.0001) to have
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graduate education in pharmacogenomic testing and personalized medicine than the other two
areas of specialization.
Stanek and colleagues conducted a cross-sectional study, utilizing a faxed survey
instrument from 2008-2012 to measure baseline levels of US physicians' knowledge and
utilization of pharmacogenomic technology in clinical practice (Stanek, Sanders, Taber 2012)
The survey instrument consisted of an anonymous questionnaire with 26 items. Fifteen were
questions about the physicians’ knowledge, attitudes, and use of pharmacogenomic technology.
An additional eleven questions captured demographics and characteristics of the clinical setting.
The instrument captured many of the constructs that were thematic in the literature. The
questions were all closed-ended and needed to be completed in entirety, otherwise the survey
was excluded. The survey instrument was based in the theoretical framework of diffusion of
innovation theory. The primary measures were to assess which factors were associated with the
decision to adopt pharmacogenomic technology. A number of variables and factors were
measured. These included many that were thematic in the literature. The sample for the survey
was drawn from a nationwide physician database obtained from Medco, a pharmacy benefit
management company for prescription drug benefits. 397,832 prescribing physicians were sent
the survey for potential participation in the study, of all physicians receiving the survey
questionnaire, only 10,003 (3%) completed and returned it. It was found that these respondents
were statistically representative of the overall physician population in the US. The internal
consistency of the survey instrument was then assessed by comparing the direction and
frequencies of responses for six pairs of related survey items. Measures were then taken to
assess the external validity of the study sample. Variables, including demographic information
and practice attributes of participants in the survey study were compared with those of the
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physician population of the United States, overall. The factors associated with the adoption of
pharmacogenomic technology were evaluated using chi-square tests and multiple regression
methods. 97.6% of participants indicated that they had some knowledge of pharmacogenomics,
but only 10.3% felt that they had an understanding of pharmacogenomic technology, adequately
enough to utilize it in the clinic.
In 2012, Dr. Susanne Haga of the Institute for Genomics Science and Policy at Duke
University, conducted the study, “Primary Care Physicians’ Knowledge of and Experience with
Pharmacogenetic Testing” (Haga, 2012). The study aimed to evaluate the knowledge level and
prior experience of pharamcogenomic technology in primary care physicians in community
practice. The survey instrument was developed through a multi-disciplinary collaboration
among investigators at Duke University and the University of North Carolina, Chapel Hill. The
instrument questions were based on a wide-scope literature review and several focus groups.
The online survey instrument was subjected to a test and re-test to validate the understandability
of the questions. A panel of primary care practitioners participated in the pre-test survey to
identify confusing questions, ambiguous terms and to assess the level of confidence in
understanding the intent of questions. The final revised survey was composed of six major
sections, totaling 101 questions in all. The concepts explored dealt with knowledge of
pharmacogenomics, experience in the clinic with pharmacogenomics, and the perceived role of
the primary care provider in delivering this technology (Haga, 2012).
Dodson and VanRiper created a survey in 2011 for a study that aimed to measure
knowledge and attitude toward pharmacogenomic technology in a large, diverse group of
providers (Dodson & VanRiper, 2011). The survey tool was based on a literature review that
highlighted many of the major concerns observed in theoretical literature. The survey was
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assessed by an interdisciplinary team of nurses, physicians and pharmacists with expertise in
pharmacogenomic testing. The tool was pilot tested on a group of five clinicians for clarity and
understandability. While the closed ended questions or replies were not published, the openended themes were analyzed in Dodson and VanRiper’s 2011 article in Personalized Medicine.
A 2012 survey by Roederer, Van Riper and colleagues measured provider knowledge,
attitudes and education concerning pharmacogenetic testing. The authors developed an online
multi-question survey that assessed healthcare provider knowledge, attitudes and education
concerning pharmacogenetic testing. The authors utilized a panel of experts from the University
of North Carolina, Center for Genomics and Society and the UNC Institute for
Pharmacogenomics and Individualized Therapy (IPIT) to evaluate the survey constructs and
provide expert opinion on content. Since the responses to the survey were anonymous, the
Institutional Review Board of UNC, Chapel Hill determined that no Institutional Review Board
review or approval was required for this study. The survey design was intended to measure not
only knowledge of pharmacogenetics, but also assess attitudes regarding pharmacogenetic
testing. The survey was evaluated by an interdisciplinary group of healthcare providers,
including nurses, physicians and pharmacists that were all considered to hold expertise in
pharmacogenetic testing. Pilot-testing of the survey was done with five healthcare providers, the
feedback results were reviewed and the survey was revised for clarity. The survey measured
various constructs that were thematic in the literature and some that were specific to this
population of pharmacy providers. There were six questions related to the general background
and demography of participants. There were two questions that measured experiential
knowledge and were designed to assess general perceptions of understanding regarding genetics
and pharmacogenetics. There were ten basic knowledge questions. Five of which, measured
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basic knowledge of genetics and five which measured basic knowledge of pharmacogenetics.
There were eight questions that assessed attitudes of pharmacists toward pharmacogenetic
testing. Two questions assessed provider interest in future educational offerings regarding
pharmacogenetic testing. The survey was sent to 9516 potential participants and over 700
pharmacists responded.
As a result of the mosaic of constructs and factors that were spread out across multiple
studies of multiple provider types, the need for the development of a new measurement tool was
apparent to meet the goals and objectives of this specific study. The PI-created PAI© study tool
was developed through a multiple stage process colloquially termed as a “modified Delphi.”
This created tool is based on constructs that are discussed thematically throughout the academic
literature regarding pharmacogenomic concerns, which were then ranked (by the
creator/principal investigator of this study) by their frequency in publications. Consensus
questions were developed and included in the PI-created PAI© tool, based on existing categories
and constructs previously developed and evaluated in prior literature. This compiled list of
questions was then compared back against the specific categories that were initially measured in
the tools that were used in previously conducted studies. Since, no study had yet looked at this
entire list of construct categories and the existing studies were limited to single or a small subset
of healthcare provider types, no one survey tool was found to be adequate for the purpose of this
study and is hence why this new tool, the PI-created PAI©, was developed.
Reliability and validity
This 46 question survey tool, the PI-created PAI©, (Appendix G) was developed by
modifying questions that showed significant findings in other studies and generating questions to
quantify constructs that had not yet been measured empirically. The questions contain either
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multiple choice, Likert scale, or bivariate, Yes/No answers. In the yes/no questions, subjects are
also given an “unsure” option to choose if they are undecided in their response. Face and content
validity was established through an expert panel review. The instrument questions were tested
for readability scores (Appendix F). A modified Delphi process was used to validate the study
instrument (Appendix H). Delphi is a technique that utilizes an expert review to establish a
consensus on the study instrument and how well its questions measure the constructs. Delphi
validation relies on convergent validity to confirm the face validity of the tool amongst blinded
experts by comparing their ratings after the fact without allowing them to discuss the content
prior to the response (Linstone, 1975). The Delphi process consisted of three rounds of blinded
panel of 5 experts that reviewed the intended constructs and provided feedback. The Delphi
worksheet requested agreement or rejection of the proposed construct that was measured by each
question. Questions that did not achieve 80% agreement were revised to include feedback from
the expert committee (Appendix I). After administration of the PI-created PAI©, the survey data
was then analyzed for reliability. The internal consistency of the PI-created PAI© tool was
assessed utilizing Chronbach’s alpha coefficient. Chronbach’s alpha is a measure of internal
consistency and is a commonly used estimate for the reliability of psychometric tests. A
psychometric instrument with an alpha score of greater than 0.6 is conventionally considered to
have acceptable internal consistency. Each of the scales was analyzed for internal consistency.
An overall alpha was calculated for each scale. The scales were also split-half analyzed and split
alphas were calculated for the paired halves. Spearman-Brown coefficients were also calculated.
The Knowledge Scale questions scored an overall Chronbach’s alpha of .770, with a split half
alpha of .603 and and .847 on the first and second halves, respectively. The Knowledge Scale
scored a Spearman-Brown coefficient of .897. The Attitude Scale questions scored an overall
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Chronbach’s alpha of .813, with an alpha of .678 and .743 on the first and second halves,
respectively. The Attitude Scale scored a Spearman-Brown coefficient of .805. The Adoption
Scale questions scored an overall Chronbach’s alpha of .853, with an alpha of .908 and .553 on
the first and second halves, respectively. The Adoption Scale scored a Spearman-Brown
coefficient of .986.
Data Analyses
Quantitative Analyses
The PI-created PAI© was closed and all data was reviewed for completeness. The data was
entered into PASW Statistics (Version 20) and stored on a portable USB flash memory drive.
That data containing flash drive was kept securely locked in a cabinet with access only by the
primary investigator, to assure data integrity. Surveys that were missing responses to greater
than 30% of the questions will be considered incomplete and were not be used in the analysis.
Otherwise, singular missing data points will be disregarded and the (n) for that calculation of that
data will reflect such.
Exploratory and descriptive components were used to further characterize the factors that are
relevant to the question of interest. Descriptive statistics were calculated for all demographic
variables, standard deviations were conducted for all continuous variables. The descriptive
statistics for demography included means, standard deviation, frequencies, and percentages.
Descriptive, exploratory data analysis methods were used to analyze the significance of
categorical factors in the context of the clinical setting (Abt, 1987).
Correlation coefficients were determined to examine the strength of relationship between
variables. The research hypotheses were tested using correlational methods, and regression
methods may be used to analyze the factors in a stepwise manner. Ratings from questions
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related to pharmacogenomic knowledge were compared with questions relating to likelihood of
adoption. Ratings from questions related to attitudes toward pharmacogenomics were compared
to ratings representing likelihood of adoption. Demography, type of provider, and the area of
specialization were analyzed in a multivariate linear regression model. The use of a multivariate
model allowed for determination of the proportion of variance that is contributed from each
factor. In a stepwise multiple regression model, each factor was added into a regression equation
individually or clustered as one construct. This allowed the model to show what proportion of
the variation in a pharmacogenomic adoption decision is contributed by constructs and by each
individual factor. In the case of ordinal-scaled variables, Spearman’s rho was used. In the case
of interval-scaled variables, Pearson’s r was determined and regression methods will be used to
determine if the independent variable has predictive strength in relation to the dependent
variable. A point bi-serial correlation was used to determine the correlation between gender and
likelihood of adoption. These tests were dependent on the underlying assumptions associated
with each. Importantly, one of the main assumptions of the parametric correlation Pearson’s r, is
that that the two variables will demonstrate covariation in a joint distribution (Portney and
Watkins, 2008). To validate this assumption, each of the data sets were checked for normality, if
either is not normally distributed, then the assumption was considered violated and rho was used.
Because any single variable may or may not be a strong predictor alone, correlations will be
calculated for each factor, however, multivariate methods were explored to determine if a more
comprehensive predictive model could be created to describe the relationship of many factors
together.
A one-way analysis of variance (ANOVA) was conducted to analyze the differences in the
responses on pharmacogenomic adoption by therapeutic area of practice. A one-way ANOVA
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was also conducted to analyze the differences in the responses on pharmacogenomic adoption by
provider type, as indicated by credentials. These tests helped to determine if there were
differences in the likelihood of adoption among different types of health care providers and if
there were differences in the likelihood of adoption among the different therapeutic areas of
practice. Using an ANOVA reduces the probability of committing a type I error, when
compared to using multiple t-tests to discern differences among multiple groups. The ANOVA
tests will be contingent to meeting the standard required assumptions of normality, independence
of observations, and homogeneity of variance. The appropriate tests were performed to
determine if these assumptions were violated in the data. If the data did not meet the
assumptions, an equivalent non-parametric test, was used and was dependent on the actual
assumption that was violated. All of the data analyzed by ANOVA was analyzed at a minimum
alpha of at least 0.05, with a targeted power of .80, which is conventionally recognized as being
adequate to protect from the possibility of committing a type II error (Portney and Watkins).
Qualitative Analyses
Additionally, the study PI-created PAI© included a number of open ended and
clarification questions that allowed a qualitative clarification on a number of issues and
questions. Though only a small amount of qualitative data was collected, relative to the
quantitative portions of the PI-created PAI©, open coding was used to analyze the responses and
the frequencies of similar responses. This allowed for potential new themes to emerge from the
study. Unlike triangulation of qualitative data, a Concurrent Embeded Strategy, embeds one type
of data collection into the other predominate form. In this case the qualitative data is considered
in context with the quantitative data question to create a fuller picture and create an “overall
composite assessment” (Creswell 2009, p. 214)
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Concurrent Embedded Design
The Concurrent Embedded Design is a mixed methods design in which one data set
provides a supportive, secondary role in a study that employs the other data type as its primary
data collection methodology. The basis for this design is that a single data set is not sufficient,
alone. Each type of data collection allows for diverse types of questions need to be answered.
Each category of question types requires unalike categories of data. This design is employed
when there is a necessity to include qualitative or quantitative data to build a composite answer
to a given a research question within a principally quantitative or qualitative study or when
additional information may be useful to support a concept, develop a finding further or
corroborate findings from the other primary method. In this study, this design was used to
embed a smaller qualitative component within a larger quantitative design (Figure 1). However,
the inverse may be true and a larger qualitative study may nest a smaller quantitative component
in some cases. In this case the primary endpoints measured for an experimental and correlational
design.
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Figure 2. Concurrent Embedded Design. This figure illustrates the elements of Concurrent
Embedded Design.
Open Coding
Open coding is one methodology for examining qualitative data. In this method of coding,
key word and key phrases are identified in an effort to establish distinct concepts and categories
within the data (Creswell, 2009). The themes that emerge then form the basic units of qualitative
analysis. The methodology then stratifies the data down into first level concepts, and secondlevel categories. In this methodology each key phrase received a category. These categories
were then transferred to a brief outline, with main concepts being main headings and categories
being subheadings.
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Chapter IV
RESULTS
Sample characteristics
The majority of participants (36.44%) were in the 40-49 years of age group. The sample
was over 58% female. Additionally, the majority of participants (44.22%) had between 20-29
years of experience in their field. 58% of respondents practiced in NJ, 17% of respondents
practiced in NY, and 16% of respondents practiced in PA, the remaining responses came from
other states in the US. 31.47% of participants worked in a private practice affiliated with an
institution. The largest group of participants (26.72%) worked in Primary Care or Internal
Medicine. The provider types were Nurses (44.68%), Physicians (33.19%), Physician Assistants
(15.32%), Pharmacists (5.96%), PhD (6.18%), and Other (2.55%).
Age
The age group with the highest representation was 40-49 year olds (35.2). Then, in
second was followed by 30-39 year olds (27%). Third largest was 50-59 year olds (22.1%). 6069 year-olds made up 9.8% of the participants and 18-29 year-olds made up 2.5% of participants.
Age was found to have a weak (ρ=.260) correlation at the p<.001 level, with adoption likelihood.
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Table 1
Participant Age Group (N=244)
Age Group
18-29 years of age
30-39 years of age
40-49 years of age
50-59 years of age
60-69 years of age

Frequency
6
66
86
54
24

Percent
2.5
27.0
35.2
22.1
9.8

Provider Type
The largest represented group of healthcare providers was nurses (41.8%). Physicians
made up the second largest provider group (31.6%). Physician Assistants were third largest
group of providers (15.2%). Pharmacists made up 4.1% and other also made up 4.1% of the
sample.
Table 2
Provider Type (N=244)
Type
MD/DO
Other
PA/PA-C
RN/BSN/LPN/NP/DNP
RPh/Pha

Frequency
77
10
37
102
10
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Percent
31.6
4.1
15.2
41.8
4.1
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Geography
Geographically, 15 states were represented, although 82% of responses came from
providers that practiced in one of three states, NJ, NY, and PA. 14.8% of participating providers
practiced in PA. 15.6% of participating providers practiced in NY. 52% of participating
providers practiced in NJ.
Table 3
State of Practice for Majority of Patient Care Activities (N=244)
State
Frequency
Percent
CA
1
0.4
CO
1
0.4
CT
6
2.5
DE
1
0.4
FL
1
0.4
KY
1
0.4
MA
1
0.4
MD
1
0.4
NJ
127
52.0
NY
38
15.6
OH
1
0.4
OR
1
0.4
PA
36
14.8
RI
2
0.8
TX
2
0.8

Therapeutic area of expertise was varied. The largest percentage of participants
specialized in Primary Care or Internal Medicine (25.4%). The second largest group was
unexpectedly, Emergency Medicine, representing 14.3% of responses. “Other” was the third
largest group and other included Radiology, Gastroenterology, Urgent Care, Hemodialysis,
Nephrology, and Rehab Medicine. Other represented 10.2% of responses for primary
therapeutic are of practice. A significant difference was found among Mean Adoption Scores by
therapeutic specialization. Though, oncology was expected to hold the highest adoption scores,
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based on the literature. It was found that Infectious Disease (20.8) was the highest mean
adoption score, followed by ENT and Genetics (20), Cardiology (19.29), and then Oncology
(18.18).
Table 4
Primary Therapeutic Area of Practice (N=244)
Therapeutic Area
Bone/ Orthopedics
Cardiology
Dentistry
Dermatology
Ear, Nose & Throat
Emergency Medicine
Endocrinology
Genetics
Infectious Disease
Oncology
Other (please specify)
Pediatrics
Primary Care/ Internal Medicine
Psychiatry
Surgery
Women’s Health/ OB/Gyn

Frequency
3
7
1
3
3
35
8
1
7
13
25
23
62
6
16
19
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Percent
1.2
2.9
.4
1.2
1.2
14.3
3.3
.4
2.9
5.3
10.2
9.4
25.4
2.5
6.6
7.8
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The majority of practitioners were in a private practice setting, affiliated with and
institution such as a hospital or university (29.9%). Employees of a hospital were the second
most represented (24.2%). Unaffiliated private practices were the third most commonly
represented group (20.9%).
Table 5
Primary Clinical Setting (N=244)
Setting
Employee of Hospital
Employee of University
Free Standing Clinic
Free-Standing Immediate Care Center
Other (please specify)
Outpatient Medical/Surgical Center
Private Medical Practice
Private Practice affiliated with Institutional Setting (e.g.
Hospital or University)
Walk-In Care Center affiliated with a Pharmacy
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Frequency
59
12
8
8
8
9
51
73

Percent
24.2
4.9
3.3
3.3
3.3
3.7
20.9
29.9

4

1.6

BARRIERS TO PHARMACOGENOMIC ADOPTION

Barriers to adoption
The most commonly cited barrier to adoption was "limited provider knowledge or
awareness" (19.5%). This was followed by lack of access to laboratory services (15.6%). "Lack
of 3rd party payor reimbursement" was the third most commonly cited barrier (13.9%). These
three responses comprised nearly 50% of the reply for this question. 5.6% of respondents did not
perceive there to be any barriers to clinical adoption. Only one respondent (0.4%) selected the
other response and provided a barrier that was not in the list. The open-end reply was “not
familiar”, which could possibly be assigned to the “limited provider knowledge or awareness”
category.
Table 6
Barriers to Adoption (N=231)
Answer Options

Response
Percent
6.1%
19.5%
5.6%
4.3%
11.3%
6.1%
13.9%
15.6%
6.5%
5.2%
5.6%
0.4%

Lack of clinical guidelines
Limited provider knowledge or awareness
Lack of evidence-based clinical information
Cost of tests is prohibitive
Lack of time or resources to educate patients
Results take too long for treatment decision
Lack of 3rd party payor reimbursement
Lack of access to laboratory services
Lack of regulatory framework
Ethical concerns over tests
Do not perceive there to be any barriers
Other (please specify)
answered question

Response
Count
14
45
13
10
26
14
32
36
15
12
13
1
231

81.5% of participants indicated that they had heard the term pharmacogenomics before taking the
PI-created PAI© , while 18.5% indicated that they had not. However, only 16.5% of participants
had observed the use of a pharmacogenomics test in clinical practice, while 77.2% had not and
6.3% were unsure if they had or not. 80% of participants indicated that they had not acquired
any information about pharmacogenomics testing outside of their clinical practice or educational
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training, while 20% indicated that they had. In those that indicated that they had and answered
the open ended question “please specify where”, the sources that they cited for acquiring
information were “white papers”, “medical journals”, “various other places” and “conferences”.
In the question of “how many times in the past year do you recall the use of pharmacogenomic
testing in the clinical setting where you work?” 87% indicated 0, 8.5% indicated 1, 3.4%
indicated 2-5, 0.56% indicated 6-9, and 0.56% indicated 10+. When asked about direct
participation in the treatment of a patient that utilized a pharmacogenomic test, 84.9% indicated
that they had not in the past year, while 7.6% indicated that they had, and 7.6% did not know.
94.3% of participants had not provided information or counseling to a patient about
pharmacogenomic tests in the last year. 5.71% of participants had provided information to
patients regarding pharmacogenomics testing in the past year, while 94.3% had not.
Instrument Scores
Table 7 shows the mean composite scores for the each category of the PI-created PAI©
instrument as well as the range of values. Zero values indicated that no questions from that
section of the PI-created PAI© were completed by at least one participant.
Table 7
Mean Instrument Composite Scores
Construct

N

Minimum Maximum Mean

Standard
Deviation

Adoption Composite Score

198

.00

24.00

14.59

7.095

Attitude Composite Score

196

.00

53.00

31.40

11.91

Knowledge Composite Score

225

.00

85.00

33.47

18.68
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Pharmacogenomic Knowledge
Participants indicated that 58.8% had taken no type of pharmacogenomic education or
training classes in the last 15 years. 23.0% indicated that they had taken a seminar. 18.6%
indicated that they had taken a college course. 14.3% indicated that they had taken a CME
course. 8.8% indicated that they had attended an in-service. In the first basic genomic and
pharmacology knowledge questions most participants (76.9%) answered correctly, identifying
two different alleles for a single trait as heterozygous. In the second basic genomic and
pharmacology knowledge questions most participants (79.6%) answered correctly, matching the
complementary strand bases to with AAGCCA with TTCGGT. In the third basic genomic and
pharmacology knowledge questions most participants (55.2%) answered correctly, identifying
the approximate number of genes in human DNA as about 22,000. In the fourth basic genomic
and pharmacology knowledge questions only 36.3% of participants answered correctly, and
identified differences in response by race as being the option most affected by genetic variations
in drug targets. In the fifth basic genomic and pharmacology knowledge questions only 34.8%
of participants answered correctly, identifying CYP2D6*10 as being most closely linked with
deficient or absent CYP2D6 activity. In the sixth basic genomic and pharmacology knowledge
questions most participants (87.3%) answered correctly and indicated that differences in a
person’s genetic profile could have an impact on how the person responds to drug treatment,
while 2.9% indicated it could not and while 9.8% did not know.
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Table 8
Knowledge Question Replies
Knowledge Question

Replies

8. Have you read any type of literature about
pharmacogenomics testing prior to taking this
survey?
11. Have you acquired information about
pharmacogenomic testing outside of your
actual clinical practice or educational
training, including CME?
13. Please indicate if you have you had any
of the following types of pharmacogenomic
education or training in the last 15 years?
(Select all that apply)

Yes 85 (39.9%)
No 128 (60.09%)
Yes 35 (19.9%)
No 141 (80.1%)
None 120 (58.8%)
Seminar 47 (23.0%)
In-Service 18 (8.8%)
College Course 38 (18.6%)
Other 2 (1%)
Correctly Answered

Knowledge Question
17. An organism that has two different alleles
for a single trait is said to be _____ for that
trait.

156 (76.9%)

18. A DNA strand has the following bases:
A A G C C A: What are the bases on its
complimentary strand?

160 (79.6%)

19. Humans have approximately the
following number of genes in their DNA:

112 (55.2%)

21. Which property is affected by genetic
variations in drug targets?

74 (36.3%)

22. Which allele is most closely associated
with deficient or absent CYP2D6 activity?

70 (34.8%)

23. Can differences in a person's genetic
profile have an impact on how the person
responds to drug treatment?

178 (87.3%)

Excellent 8 (4.2%)
Very Good 35 (18.5%)
Good 58 (30.7%)
Fair 57 (30.2%)
Poor 31 (16.4%)

38. How would you rate your current
understanding of pharmacogenomic testing?
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Self-assessment of knowledge
A comparison was made to gauge how strong the relationship was between participants
own perception of their understanding of concepts related to pharmacogenomic testing and the
accuracy of their respective replies to the instrument’s knowledge questions. A significant
correlation was found to exist (ρ=.812, p<.001) between self-rating and actual knowledge
composite scores. This suggests that individual’s perceptions of their pharmacogenomic
knowledge were closely linked to their knowledge composite scores, as measured by the
instrument.

Figure 3. Correlation between self-rating and knowledge question scores. This scatter plot
illustrates the relationship between pharmacogenomic knowledge and self-rating of knowledge.
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Attitude towards pharmacogenomics
In the question of attitude toward pharmacogenomics as a valuable diagnostic tool in the
treatment of patients 45.6% of participants indicated that pharmacogenomics was a valuable
diagnostic tool, 40.9% indicated that it had some value, 2.1% indicated it had no value and
11.4% had no opinion on the value of pharmacogenomics as a diagnostic tool in the treatment of
patients. The most common response in the question of pharmacogenomics offering an eventual
cost reduction in developing new drugs was that it was perceived to be somewhat likely (29.9%),
while 28.6% of respondents thought it was neither likely nor unlikely, 13.9% replied somewhat
unlikely, 12.4% replied very likely, 6.7% replied very unlikely and 8.7% had no opinion. When
asked if pharmacogenomic testing was likely to help increase drug safety, most respondents
(38.1%) replied that it was somewhat likely, while 27.8% replied that it was very likely or it
already had, 22.7% replied that it was neither likely or unlikely. Only 3.6% replied that it was
somewhat unlikely, and 2.1% that it was very unlikely. When asked how likely it was that
genetic data collected for the purpose of patient treatment was to be misused the most common
reply was that it was neither likely nor unlikely (36.6%), while 26.3% indicated that it was
somewhat unlikely and 19.6% thought that it was somewhat likely that genetic data could be
misused. When asked if concerned that a patients quality of healthcare may be adversely
affected by the results of their pharmacogenetic testing, the majority of respondents (39.5%),
were again neither concerned nor unconcerned, 26.3% were mostly unconcerned, 23.2% were
somewhat concerned, 4.2% were completely unconcerned, and 2.6% were very concerned. 4.2%
replied that the concern was not relevant to their area of practice. When asked if concerned that
the results of pharmacogenomic testing could result in discrimination by insurance companies,
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the majority of respondents (37.8%) indicated that they were somewhat concerned. 26.4% were
neither concerned nor unconcerned, 20.2% were mostly unconcerned, 9.3% were very
concerned, 1.5% were completely unconcerned and 4.6% believed the concern to be not relevant
to their area of practice. 32% of respondents were mostly concerned that the results of
pharmacogenomic testing could result in discrimination in employment, while 29.9% were
neither concerned nor unconcerned, 19.6% were somewhat concerned, 6.7% were completely
unconcerned, 4.1% were very concerned and 7.7% believed that the concern was not relevant to
their area of practice. When questioned about the cost of genomic testing and whether or not it
was likely to be a deterrent to the utilization of pharmacogenomic technology in the clinic, the
majority of respondents (42.8%) indicated that it was neither likely nor unlikely to be, while
22.7% indicated that it was perceived to be somewhat likely, 14.4% indicated that they perceived
that it was somewhat unlikely, 10.3% indicated that they perceived the cost to be a likely factor
in deterring the utilization of pharmacogenomic testing in the clinic, 2.1% said it was very
unlikely, 7.7% had no opinion. When asked if they believed that pharmacogenomic testing is
difficult for healthcare providers to understand, 23.7% of respondents replied yes, while 61.3%
of respondents replied no and 15% of respondents had no opinion. When asked if they believed
that pharmacogenomic testing is difficult for patients to understand, 34.7% of respondents
replied yes, while 47.9% of respondents replied no and 17.5% of respondents had no opinion.
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Table 9
Attitude Question Replies
Attitude Question

Replies
Has a lot of value 88 (45.6%)
Has some value 79 (40.9%)
Has no value 4 (2.1%)
Have no opinion on value 22 (11.4%)
Very unlikely 13 (6.7%)
Somewhat unlikely 27 (13.9%)
Neither likely or unlikely 55 (28.6%)
Somewhat likely 58 (29.9%)
Very likely/ It already has 24 (12.4%)
No opinion 17 (8.7%)
Very unlikely 4 (2.1%)
Somewhat unlikely 7 (3.6%)
Neither likely or unlikely 44 (22.7%)
Somewhat likely 74 (38.1%)
Very likely/ It already has 54 (27.8%)
No opinion 11 (5.7%)

26. Do you believe that pharamacogenomics
is a valuable diagnostic tool in the treatment
of patients?
27. Do you believe that pharmacogenomic
testing will help to offer an eventual cost
reduction in developing new drugs?

28. Do you believe that pharmacogenomic
testing will help to increase drug safety?

29. In your opinion, how likely is genetic
data, that is collected for the purpose of
patient treatment, to be misused?

Very unlikely 11 (5.7%)
Somewhat unlikely 51 (26.3%)
Neither likely or unlikely 71 (36.6%)
Somewhat likely 38 (19.6%)
Very likely/ It already has 11 (5.7%)
No opinion 12 (6.2%)

30. Are you concerned that a patient’s quality
of healthcare may be adversely affected by
the results of their pharmacogenetic testing?

Completely unconcerned 8 (4.2%)
Mostly unconcerned 50 (26.3%)
Neither concerned or unconcerned 75 (39.5%)
Somewhat concerned 44 (23.2%)
Very concerned 5 (2.6%)
Not relevant to my area of practice 8 (4.2%)
Completely unconcerned 3 (1.5%)
Mostly unconcerned 39 (20.2%)
Neither concerned or unconcerned 51 (26.4%)
Somewhat concerned 73 (37.8%)
Very concerned 18 (9.3%)
Not relevant to my area of practice 9 (4.6%)

31. Are you concerned that the results of
pharmacogenomic testing could result in
discrimination by insurance companies?

32. Are you concerned that the results of
pharmacogenomic testing could result in
discrimination in employment?

Completely unconcerned 13 (6.7%)
Mostly unconcerned 62 (32.0%)
Neither concerned or unconcerned 58 (29.9%)
Somewhat concerned 38 (19.6%)
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Very concerned 8 (4.1%)
Not relevant to my area of practice 15 (7.7%)
33. Do you believe that the cost of genomic
testing is likely to be a deterrent to the
utilization of pharmacogenomic technology
in the clinic?

Very unlikely 4 (2.1%)
Somewhat unlikely 28 (14.4%)
Neither likely or unlikely 83 (42.8%)
Somewhat likely 44 (22.7%)
Very likely/ It already has 20 (10.3%)
No opinion 15 (7.7%)

34. Do you believe that pharmacogenomic
testing is difficult for healthcare providers to
understand?
35. Do you believe that pharmacogenomic
testing is difficult for patients to understand?

Yes 46 (23.7%)
No 119 (61.3%)
No opinion (15.0%)
Yes 67 (34.5%)
No 93 (47.9%)
No opinion (17.5%)

Experience question replies
Experience questions were originally allocated as a sub-set of knowledge, however, in the
Delphi validation process of the Pharmacogenomic Adoption Instrument, a consensus of experts
agreed that experiential knowledge was distinct from academic knowledge and should be
measured independently. When asked if respondents had heard the term pharmacogenomics
before taking this survey, 87.1% replied yes, while 18.3% replied no. When asked if respondents
had observed the use of pharmacogenomic tests in clinical practice, at any time in the past year,
16.4% replied yes, while 77.4% replied no and 6.2% were unsure.
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Table 10
Experience Question Replies
Experience Question

Replies

9. Have you heard the term
pharmacogenomics before taking this survey?

Yes 187 (81.7%)
No 42 (18.3%)

10. At any time in the past year, have you
observed the use of pharmacogenomic tests
in clinical practice?

Yes 29 (16.4%)
No 137 (77.4%)
Unsure 11 (6.2%)

13. In the past year, how many times do you
recall the use of pharmacogenomic testing
information by anyone, in patient treatment,
in the clinical setting where you work?

0
1
2-5
6-9
10+

155
15
6
1
1

(87.1%)
(8.4%)
(3.4%)
(0.6%)
(0.6%)

14. In the past year, have you directly
participated in the treatment of a patient that
utilized a pharmacogenomic test?

Yes 13 (7.5%)
No 147 (85.0%)
Do not know 13 (7.5%)

17. In the past year, have you provided
information or counseling to a patient about
pharmacogenomic tests?

Yes 10 (5.7%)
No 166 (94.3%)

16. Have you ever recommended that a
patient undergo pharmacogenomic testing?

Yes 16 (9.0%)
No 161 (91.0%)
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Results of Test Hypotheses
Hypothesis 1a analysis
Research hypothesis 1a posited that a relationship would exist between likelihood to
adopt and demographic factors. This first question looked at relationships between likelihood to
adopt and demography. The factor age was treated as an ordinal level variable, as age was
measured in graduated groups. The factor years of experience was also treated as an ordinal
level variable, as years of experience were measured in graduated groups. The factor gender was
treated as a nominal variable. Since gender was a dichotomous variable, it was analyzed using
point bi-serial correlation. The two ordinal level factors were age and years of experience. The
data were assessed for the assumptions of independence, normality, and homogeneity of
variances. The factors were analyzed for correlation with likelihood to adopt, as measured by
adoption composite score, using a Spearman bivariate test of correlation. Years of Experience
yielded very weak (ρ=.148, p<.05), but significant correlation. Age yielded a weak (ρ=.260,
p<.001) correlation.
Table 11
Correlation matrix age, years of experience, and adoption composite score
Years of

Factor

Experience
Years of Experience

Correlation Coefficient

Adoption Composite Score

Age

Composite
Score

1.00

.60

.15

.

.001

.05

N

23

224

190

Correlation Coefficient

.60

1.000

.26

Sig. (2-tailed)

.001

.

.001

N

224

236

197

Correlation Coefficient

.15

.26

1.00

Sig. (2-tailed)

.05

.001

.

N

190

197

197

Sig. (2-tailed)
Age

Adoption
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An ANOVA of Adoption Composite scores showed that there was a significant
difference between males and females at p<.05, but the effect size was small. An Eta squared of
.028 indicated that, at most, 2.8% of the variation between adoption scores could be attributed to
gender (among other possible factors). Since gender was a nominal variable, the only correlative
measure that could be used was a point bi-serial correlation. A point bi-serial correlation test,
yielded a moderate significant correlation (ρ =.190, p<.01) between gender (coded) and
Adoption Composite Score.
Table 12
Point Bi-serial correlation matrix of gender by adoption score
Adoption
Test

Composite

Gender Coded

Score
Spearman's rho

Adoption Composite Score

Correlation Coefficient

1.00

Sig. (2-tailed)
Gender Coded

.190
.009

N

197

197

Correlation Coefficient

.190

1.00

Sig. (2-tailed)

.009

N

197

236

Hypothesis 1b analysis
Hypothesis 1b predicted that a significant difference would exist in adoption scores
among different therapeutic areas of practice (e.g. oncology, cardiology, primary care).
Differences in Mean Adoption Scores were compared by therapeutic area. Though oncology
was expected to hold the highest adoption scores, based on the literature, it was found that
Infectious Disease (20.8) was the highest mean adoption score, followed by ENT and Genetics
(20), Cardiology (19.29), and then Oncology (18.18).
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Figure 4. Likelihood of adoption by therapeutic area. The above figure illustrates the mean
adoption scores of providers by their primary therapeutic area of practice, as defined by 50% or
greater of their caseload.
An ANOVA was performed to test for differences in adoption scores by therapeutic area.
An ANOVA of Adoption composite scores (F(16,186) =2.20, p<.01) showed that there was a
significant difference among specializations at the p<.01, but the effect size was small. An Eta
squared of .171 indicated that, 17.1% of the variation between adoption scores could be
attributed to specialization (among other possible factors).
Hypothesis 1c analysis
Hypothesis 1c predicted that a significant difference would exist in likelihood to adopt
among different types of healthcare providers (e.g. MD, NP, PA, etc.). Differences in Mean
Adoption Scores were compared by therapeutic area. As expected from the extrapolating from
the literature, Pharmacists had the highest likelihood to adopt with a Mean Adoption Composite
Score of 19.5. This was followed by physicians, PA’s then Nurses. Degrees and/or credentials
representing other types of providers included DMD, CRNA, RD and ATC.
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Figure 5.. Likelihood
d of adoption
n by providerr type. The above bar grraph illustrattes mean
adoption composite scores
s
by pro
ovider type.
The
T data weree assessed fo
or the assum
mptions of inddependence,, normality, homogeneityy of
variancess. An ANOV
VA of Adopttion Compossite Scores s howed that tthere was a ssignificant
differencce (F(5,186)=
=2.43, p<.05
5) among pro
ovider types at the p<.055 level, but thhe effect sizze
was again
n small. An
n Eta squared
d of .063 ind
dicates that, 66.3% of the vvariation bettween adopttion
scores caan be attributted to provid
der type (am
mong other poossible factoors).
Hypotheesis 2 analyssis
Hypothesis
H
2 predicted th
hat a relation
nship would exist betweeen knowledgge of
pharmaco
ogenomic teesting and thee likelihood of adoptionn of pharmaccogenomic teesting by
healthcarre providers in the cliniccal setting.
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Figure 6.. Scatterplot of adoption
n composite score
s
by knoowledge com
mposite scoree. The abovve
scatterplo
ot illustrates the distribu
ution of know
wledge vs. addoption com
mposite scorees.
The
T data weree assessed fo
or the assum
mptions of inddependence,, normality aand
homoscedasticity. A formal test of
o correlatio
on shows thaat, indeed, knnowledge ovverall, as a
constructt, correlates with adoptio
on (ρ =.767, p<.001). Siince some off the data oriiginated from
ma
Likert typ
pe scale, it was
w treated as
a ordinal lev
vel data. Thhere is some amount of ddisagreementt
among pu
ublications as
a to what th
he level of measurement
m
when it is partt of
of this type of data is w
an instrum
ment. Thou
ugh, there waas still a strong significannt correlatioon when the P
Pearson r waas
calculated.
Hypotheesis 3 analyssis
Hypothesis
H
3 predicted th
hat a relation
nship would exist betweeen attitude toowards
pharmaco
ogenomic teesting and thee likelihood of adoptionn of pharmaccological testting by
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healthcare providers in the clinical setting. Figure X shows the scatterplot of the Attitude
Composite Scores, as compared to Adoption Composite Scores along with the best fit linear
trend line for this data.

Figure 7. Scatterplot of adoption composite score by attitude composite score. The above
scatterplot illustrates the distribution of knowledge vs. adoption composite scores.
The data were assessed for the assumptions of independence, normality and
homoscedasticity. Since some of the data originated from a Likert type scale, it was treated as
ordinal level data. A formal Spearman test of correlation showed that attitude correlated with
adoption (ρ =.798, p<.001).
The overall mean for Adoption Composite Score was 31.40. Among provider types, pharmacists
were found to have the highest attitude composite scores ( x =42.25), indicating the most positive
attitude toward pharmacogenomic technology. This was followed by the provider type,
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physician
ns ( x =33.58
8). Nurses and
a physician
n assistants ooverall, scorred close to tthe same, buut fell
below thee mean with
h scores of 29
9.68 and 29.48, respectivvely.

Figure 8.. Mean adop
ption compossite score by
y provider tyype. The aboove bar graphh illustrates the
mean ado
option comp
posite score by
b type of heealthcare proovider.
Hypotheesis 4 analyssis
Hypothesis
H
4 posited thatt a model wo
ould exist thaat would besst predict thee probabilityy of
adoption of pharmacogenomic teechnology in
n clinical praactice. The aaim of this reesearch quesstion
m
The table below shows the rrespective reegression coeefficients of each
was to deescribe this model.
factor. The
T factors considered were
w age, yeaars of experieence, pharm
macogenomicc experience,,
academicc knowledgee, clinical ben
nefit, and co
ost effectivenness, potentiial for misusse and/or
discrimin
nation, and patient/provi
p
der ability to
o understandd. Variabless that were foound to be
multicolllinear were excluded
e
from the regresssion analysiis.
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Table 13:
Regression Model of Factors Predicting Adoption Composite Scores
Model
(Constant)

B

Std. Error Beta

t

Correlations
Sig. Zero-order Partial Part

-1.870

2.860

-.654 .514

Age

.238

.405

.038

.587 .558

.186

.048

.031

Years of Experience

-.252

.828

-.020 -.304 .761

.188

-.025

-.016

PGx Experience

-.040

.066

-.052 -.616 .539

.458

-.050

-.032

Academic Knowledge

.084

.060

.156 1.412 .160

.651

.115

.074

Clinical Benefit

.676

.196

.302 3.453 .001

.698

.272

.181

Cost Effectiveness

.371

.213

.124 1.742 .084

.564

.141

.091

Misuse/Discrimination

.496

.233

.142 2.126 .035

.536

.172

.111

Patient/Provider Understand

.410

.126

.242 3.266 .001

.636

.258

.171

A regression model was generated for adoption composite scores. Factors that were
found to have significant effect in the previous ANOVAs were utilized as predictor variables. A
forward regression model was first completed. The forward regression revealed a significant
model (F(8,157)=27.02, p<.001). A backward elimination was then performed. Among the
predictor variables in the forward model, Clinical Benefit, Attitude toward Misuse or
Discrimination, and Ability for Patient/Provider to Understand, were found to be statistically
significant in predicting likelihood of adoption of PGx technology. The forward model was
determined to be the best fit, because it yielded the lowest Akaike information criterion (AIC).
Akaike weights can be used in model averaging. They represent the relative likelihood of a
given model. To calculate the AIC for each model the relative likelihood of the model was first
determined, using the equation, exp ( -0.5 * ∆AIC score for that model). The Akaike weight for
the model was this value divided by the sum of these values across all models. Based on this, the
following regression equation was be generated: Likelihood of Adoption = .68(Clinical Benefit)
+ .50(Attitude toward Misuse/Discrimination) + .41(Ability to Understand) – 1.87.
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Summary
A weak relationship existed between likelihood to adopt and the demographic factors of
age, years of experience. There was a significant difference between genders, but effect size was
very small. Infectious Disease practitioners had the highest likelihood of adoption. A significant
difference existed among specializations, 17.1% of the variation between adoption scores can be
attributed to specialization. A significant difference was found to exist among provider type
groups. Pharmacists had the highest likelihood of adoption, 6.3% of the variation between
adoption scores can be attributed to provider type. A strong correlation (ρ =.767, p<.001) was
found between knowledge of pharmacogenomic testing and the likelihood of adoption of by
healthcare providers in the clinical setting. A strong correlation (ρ =.798, p<.001). was found
between attitude towards pharmacogenomic testing and the likelihood of adoption of
pharmacogenomic testing by healthcare providers in the clinical setting. Among the predictor
variables examined, Clinical Benefit, Attitude toward Misuse or Discrimination, and Ability for
Patient/Provider to Understand, were found to be statistically significant in a model predicting
likelihood of adoption of PGx technology.
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Chapter V
DISCUSSION
General discussion of key study findings
This study investigated factors that contributed to the likelihood of adoption. The study
measures were centered around constructs emergent from the health belief model and Rogers
Diffusion of Innovation theory. Though previous literature has identified a number of barriers
that could inhibit the use of pharmacogenomic testing, this study specifically, empirically
investigated a number of these factors and what their relationship to adoption of this technology
was in clinical practice. Studies, such as Condit’s 2003 work, have investigated some factors,
but only in one group of providers, in this case physicians. This study looked at factors that were
common among many healthcare provider types, such as physician assistants, nurse practitioners
and others have a direct role in patient prescribing and these groups perceptions of many of the
issues discussed had yet to be captured, side by side in a an empirical study. This study also
compared the effect of therapeutic specialization and found that there was a difference between
specializations in likelihood to adopt. This study allowed for an overall assessment of the
composite barriers that emerged from the present literature. It also allowed for a direct
comparison between groups with the questions standardized to a single instrument, allowing for
a side by side comparison of perception between provider type groups, different therapeutic areas
and a number of other factors.
Barriers to adoption
This dissertation study found the most commonly cited barrier to adoption to be limited
provider knowledge or awareness, which was consistent with Bonter’s 2011 study (Bonter,
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Desjardins, Currier, Pun, & Ashbury, 2011) that found limited knowledge to be the second most
cited factor among Canadian physicians. This was followed by lack of access to laboratory
services (15.6%). "Lack of 3rd party payor reimbursement" was the third most commonly cited
barrier (13.9%). These three responses comprised nearly 50% of the reply for this question.
Though many barriers that had ranked highly in previous studies, they were not found to be
statistically significant in this study. For instance, in Bonter’s study a “lack of evidence-based
clinical information” was cited as the third most highly cited barrier to adoption (Bonter,
Desjardins, Currier, Pun, & Ashbury, 2011). Though, in this dissertation study, “lack of
evidence based clinical information” was in the lower half of responses for greatest perceived
barriers by frequency. There is some discord in the consensus on the level of evidence required
to recommend clinical pharmacogenomics tests. Though this dissertation study and Bonter’s
study had different finding in terms of validation required by clinical evidence, other studies
have had mixed results on this topic (Guzauskas, Serbin, & Veenstra, 2015). The objective of
Guzauskas’ study was to quantitatively compare the evidence levels of two contested drugattenuating interactions and assess the value of obtaining additional evidence to inform clinical
practice guidelines. Guzauskas’ findings suggested that there was not a clear consensus in
weighting the value of the evidence in each case. Overall, it is likely that a more in depth
assessment of the validation of pharmacogenomic evidence levels in relation to other clinical
interventions is needed as a helpful tool to guide policy makers in evaluating the clinical
importance of evidence in test recommendations.
Other factors, such as cost-effectiveness have become less significant as the landscape
and technology has changed since earlier studies were conducted. Studies such as Wong had
previously looked at cost-effectiveness and the cost effectiveness of pharmacogenomic
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technology was reported to be a significant factor in utilization decision making (Wong, Carlson,
Thariani, & Veenstra, 2010). This study, however, did not find cost-effectiveness to be a
statistically significant factor in determining the likelihood of adoption of pharmacogenomic
technology. Dynamic factors like the cost of tests have dramatically fallen in the past decade,
making previous assessments of cost to benefit less relevant to today’s landscape. A 2015
assessment of cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug
reactions found cost-effectiveness to be highest ever reported (Alagoz, Durham, & Kasirajan,
2015). Additionally, the predictive value of tests has improved and expanded in more recent
years. Thus, cost has become perceived by many to be less of a barrier, than it had been
previously. It has now become more widely accepted that the relatively reduced cost of
genotyping is far outweighed by the clinical utility of the genotyping information. This may
explain why cost has previously been found to be a prohibitive factor in the adoption of
pharmacogenomic testing in previous studies, but was not found to be a significant factor in this
study. The changing healthcare landscape and the changing of the technology that comprises
innovation in pharmacogenomics create a fluid model, in which factors may rise and fall in their
relationship with adoption outcomes and with respect to their place in a model of the process.
Demography
The first research question looked at the relationship between likelihood to adopt and
demographic factors. The weak correlation between age and adoption likelihood and the weak
correlation between years of job experience suggest there is a relationship between these
variables; however the amount of variation that could be attributable was very small, when
considered in the regression model. The demographic factors, while statistically significant,
didn’t appear to yield a large effect size in terms of variation in adoption likelihood outcomes.
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However, an ANOVA of Therapeutic Specialization did yield an eta squared of about 17%. This
was corroborative with the qualitative finding that the Emergency Medicine and Urgent Care
settings may have a lower likelihood of adoption than other settings. Though other studies have
found differences to exist among physicians by therapeutic specialization, this was the first to
identify Emergency Medicine and Urgent Care as different from other specializations in potential
for adoption (Swen and Guchelaar, 2012; Stanek, Sanders, & Taber, 2012).
Pharmacogenomic knowledge
Findings from the study were consistent with other studies in the literature. The study
findings on knowledge were in line with the predictions of adoption in other study populations.
In Stanek’s 2012 study of physician adoption, 97.6% of physicians that responded believed that a
patient’s genetics could affect their response to a drug, whereas in this study of healthcare
providers as a whole, only 87.3% answered yes to a similar question (Stanek, Sanders, Taber,
2012). This further supports the thought that physicians may have better knowledge of
pharmacogenomics than healthcare providers, overall. A theme that emerged in the open-ended
portion of this study was that insufficient knowledge or training was available. This is consistent
with Haga’s study of primary care providers of the primary barriers in this group. In Haga’s
study it was cited that there was limited opportunity to utilize this technology in practice (Haga,
2012). This study also found that knowledge was insufficient in primary care providers and that
limited training opportunities and limited access to information portals made primary care
physicians less confident in utilizing this technology to guide a diagnosis. This suggests that not
only primary care physicians, but perhaps all non-specialized clinical healthcare providers, as a
whole face challenges that are unique to that circumstance. The results of this study would be in
accord with Swen’s posit that these issues may be related to previous opportunity to gain
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experience, a lack of knowledge and inadequate access to information. This study and Haga’s
indicate that primary care providers have a desire to provide pharmacogenomic testing and
utilize the results for clinical guidance, but knowledge and training opportunities are limited and
this are preventative.
Academic Knowledge
Knowledge, overall, was strongly correlated with increased adoption composite scores.
However, academic knowledge alone was not found to be a significant predictor in regression
analysis. This suggests that acquiring of knowledge of pharmacogenomics may be a necessary
step in the adoption process, but it is not necessarily sufficient as a factor to predict adoption
behaviors. While those that had a low likelihood of adoption typically scored low in knowledge,
many that scored high in knowledge had a somewhat low likelihood of adoption. This suggests
that knowledge of basic genomics and theoretical knowledge of the underlying scientific
mechanisms for the pharmacogenomic test, may be less important to a diverse group of
healthcare providers than the experiential knowledge gained from hands-on experiences in
clinical practice. It may be that many of the physician extenders did not necessarily believe that
understanding basic genomics was directly related to their role or the scope of their role within
the clinical setting. Among the many measured factors that made up the domain of knowledge in
the instrument, the only one that was found to be predictive of adoption outcomes was
experiential knowledge or observation of pharmacogenomics in the clinical setting. Experience
with pharmacogenomics was found to be thematic in the qualitative responses, as well. This
finding suggests that academic knowledge alone may not sufficiently support the factor of
observability, as described by Roger’s theory, while experiential knowledge may produce its
effect on observability. Observability influences the domain of persuasion, thus it is a key factor
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in the decision making portion of the adoption process. This concept is one of the five elements
that describe direct influence to the persuasion domain. Persuasion factors are latter stage of the
adoption process, as compared to knowledge and attitude factors. Thus, these factors are more
likely to be predictive of adoption than others. Not knowing all of the specific factors that
comprise the concept of experiential knowledge and “in the clinic training”. It is difficult to
determine how the variation is spread amongst this construct. What can be inferred is that,
though academic knowledge was not found to be a predictive factor, experiential knowledge,
which was, may be a factor that accounts for some of the unexplained variation, in the best fit
regression model. Stanek’s study, a majority of physicians reported that they believed that a
person’s genetics influenced their drug response (Stanek, 2012). This dissertation study had
similar findings, though in this study the role of knowledge was slightly more nuanced. The
increasingly rapid development of discovery in pharmacogenomics will drive an urgency to
expand medical school curricula to include components that address the role of
pharmacogenomic testing and integration of this technology into clinical practice. Inferences
from this study suggest that when developing educational materials, it is as, if not more
important to include the humanities of pharmacogenomics in the curricula, as it is to include the
molecular and biological basis of the technology. Information about privacy protections; legal
and social protections against misuse and discrimination; informed consent in
pharmacogenomics, are all equally important to inform future healthcare providers on and
knowledge of these topics may have a greater impact on the adoption of this technology in
students, that the molecular basis for the tests. A recent study compared knowledge, attitudes
and practices of student physicians and student pharmacists in Malaysia (Yau & Haque, 2016).
The findings of Yau’s study were in alignment with the implication discussed here.
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Accordingly, healthcare organizations and government authorities will have to drive forward the
task of medical schools with training future healthcare providers to be competent in their
knowledge of genomic implementation and to understand the social context and mechanisms of
this technology in their respective settings.
Attitude
Attitude factors were the strongest predictors in the regression model for likelihood of
adoption of phamacogemonic technology in the clinic. The attitude composite score was highly
correlated with the adoption composite score. Findings from the literature showed that early and
future adopters of pharmacogenomic testing were more likely to have received training in
pharmacogenomics, and that only a third of physicians, overall had received any education in the
field (Stanek, 2012). However, this dissertation revealed that while knowledge was correlated to
adoption, it was not necessarily a strong predictor for high likelihood of adoption as a factor.
This suggests that the variation in adoption likelihood from knowledge, overall, is likely shared
with other factors and that knowledge may be a necessary factor, but not one sufficient to change
adoption outcomes. Thus, in other provider type groups, many of the high adoption scorers
were not associated with the expected training or education in pharmacogenomics. These
findings highlight the need for more effective education on topics related to attitude in
diversified provider groups on the clinical benefit, misuse and discrimination, and understanding
of and interpretation of pharmacogenomic tests between providers and patients. It was expected
from previous findings in the literature that age and attitude could have a relationship, however,
no significant relationship was found to exist. Among providers, pharmacists had the highest
attitude scores, followed by physicians, these two groups scored higher than the overall mean,
suggesting that these two groups had a more positive attitude toward pharmacogenomics. Nurses
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and physician assistants fell below the overall mean, suggesting that they have a less favorable
attitude toward pharmacogenomics than the aforementioned groups. These findings were
consistent with Roederer’s 2012 study of pharmacists and Stanek’s 2012 study of physicians.
Clinical Benefit
Clinical benefit was found to be one of the three significant predictor variables in the
best fit regression model. This suggests that the perception of a benefit to using
pharmacogenomics is a significant factor that has a strong predictive value in the adoption
process. This finding speaks to the concept of Relative Advantage in Roger’s theory (Rogers,
2010). While Clinical Benefit was categorized as an attitude factor, the perception of relative
advantage exerts its effects on persuasion. That is, that the user must perceive the innovation to
provide an advantage in its use, when compared to the alternatives. This concept is one of the
five elements that describe direct influence on the persuasion domain of Rogers stages of
adoption. Persuasion factors are in the latter stage of the adoption process, as compared to
knowledge and attitude factors, indicating that requisites for knowledge and attitude have been
satisfied and the potential adopter has progressed to the persuasion stage. Thus, these factors
are more likely to be predictive of adoption than the others prior stage factors.
Recently, a study by Guzauskas assessed the value of obtaining additional evidence to
inform clinical practice guidelines (Guzauskas, Serbin, & Veenstra, 2015). In weighting
evidence, it was found that consensus was unclear as to what constituted clinical value. So,
though clinical benefit is a highly predictive factor in relation to adoption, the precise factors
that create value are subjective and are different among providers. These findings are in
agreement with what McKinnon found in a 2010 study. McKinnon’s 2010 paper suggested that
there is complexity in weighing the cost benefit of pharmacogenomic technology by healthcare
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payers, because of the different efficacy associated with different markers (McKinnon, 2010).
This dissertation study found that increased drug safety and improved probability of efficacy
were both contributing factors to the perception of clinical benefit. Though, clinical value and
benefit is clearly a significant factor, the significant components that comprise value and benefit
may be differentially focused among different provider groups. This corroborates the notion in
Roger’s theory that Relative Advantage is a subjective consideration and that when determining
value or benefit, the endpoints for making the determination, may be highly individualized.
Cost Effectiveness
Cost-effectiveness was not found to be a significant factor in this study. This is in
disparity with prior studies, but may be found to be in alignment with future studies. In the
contemporary background, cost may be becoming increasingly less significant as a factor.
Further, pharamcogenomic technology has improved in efficacy and predictive value since many
of the earlier studies were conducted. As mentioned, Studies such as Wong’s had previously
looked at cost-effectiveness of pharmacogenomic technology. Though it had previously been
reported to be a significant factor in adoption decision making, this dissertation study found
evidence to the contrary (Wong, Carlson, Thariani, & Veenstra, 2010). This dissertation study
did not find cost-effectiveness to be a statistically significant factor in determining the likelihood
of adoption of pharmacogenomic technology. This may be due the inherent changes in cost
mentioned earlier. A 2015 assessment of cost-effectiveness of one-time genetic testing to
minimize lifetime adverse drug reactions found cost-effectiveness to be highest ever reported
(Alagoz, Durham, & Kasirajan, 2015). Additionally, the predictive value of tests has improved
and expanded in more recent years. Thus, cost has become perceived by many to be less of a
barrier, than it had been previously. It has now become more widely accepted that the relatively
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reduced cost of genotyping is far outweighed by the clinical utility of the genotyping
information. This may explain why cost has previously been found to be a prohibitive factor in
the adoption of pharmacogenomic testing in previous studies, but was not found to be a
significant factor in this study. The changing healthcare landscape and the changing of the
technology that comprises innovation in pharmacogenomics create a fluid model, in which
factors may rise and fall in their relationship with adoption outcomes and with respect to their
place in a model of the process.
Misuse and discrimination
One of the most thematic factors in this dissertation study was the perception for potential
for misuse and discrimination as a barrier to adoption. This factor was another that was highly
predictive of adoption outcomes. As in previous studies, one of the most concerning issues is the
utilization of pharmocogenomic technology and the protection of a patient’s privacy and the
potential for future discrimination based on genetic information. This study asked about the
potential for genetic discrimination by health insurance companies, genetic discrimination, by
employers, privacy concerns and general misuse of data collected for the purpose of patient
treatment. A recent study found similar results in physicians, and found that these physicians
had lower knowledge of protections against discrimination (Laedtke, O’Neill, Rubinstein, &
Vogel, 2012). This study found that knowledge was limited regarding the existence of
protections against misuse, and the pertinent facts about these protections. Though in Laedtke’s
study, physicians who were aware of legal protections persisted to have major apprehensions
concerning the potential risk of genetic discrimination. Thus, even when educated further on the
topic, adoption would not likely improve. This may suggest that knowledge alone is not
sufficient and vicarious observation may be required to internalize the value of legal and social
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protections. Both studies suggest that there is a need to further educate physicians about the
existence of protections, and that this education may need to be supplemented with hands-on
activity to aid in internalizing the value of these protections.
Since patient genetic information is highly permanent and can potentially contain
significant information about an individual’s health predispositions, the implications related to
concerns of misuse of this data is likely a great consternation factor in the perception of
providers (Rogausch et al, 2006). The data collected in pharmacogemonic tests is highly
sensitive and identifies information that may be highly predictive of an patients health outcomes.
Evidently, the permanent and highly confidential nature of genomic offers the potential for a
great risk of loss of confidentiality (Goldman, 2005). The suggestion of this study in conjunction
with the literature is that providers perceptions of the protections for the potential misuse of this
information could have grand the resultant consequences to patients are highly influential in the
adoption process.
Knowledge of data encryption and the rigorous confidentiality standards that protect
patients from genetic discrimination is likely a proximal factor that effects perception of the
potential for these events. In the US, privacy protection and data handling laws regarding
genetic information have become steadily more and more stringent with the aim of protecting
patients. In the US, the Genetic Information Non-discrimination Act of 2008 protects patients
from misuse and discrimination by legally prohibiting health plans, insurers and employers from
denying coverage or charging higher premiums to individuals based on genetic predisposition
(NHGRI, 2008). The legal statute's mission language proposes “to fully protect the public from
discrimination” and “allay their concerns about the potential for discrimination, thereby allowing
individuals to take advantage of genetic testing, technologies, research and new therapies.”
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Though, this legal protection and others are currently in place, this dissertation study still found
that perceived potential for genetic misuse and discrimination was a strong predictive factor in
the adoption process and that a large portion of responders with low adoption had negative
attitudes toward the potential for misuse and discrimination, meaning that the perceived these
events to be likely to happen.
Provider ability to explain/Patient ability to understand
The final factor that was quantitatively significant in the regression model was related to
the ability of providers to effectively explain the implications and results of pharmacogenomics
tests to patients and the patients’ ability to understand the information provided. This factor
relates to the complexity concept in Roger’s Diffusion of Innovation Theory (Rogers, 2010).
Some studies have shown that when clinicians provide explanation for genomic tests, the patient
may sometimes overestimate the clinical benefit, thus it is important that the provider be able to
adequately describe the nature of a specific test and markers and clearly be able to detail the
exploratory nature of any components (Brewer et al., 2014). Providers need to have an adequate
base of knowledge to be able to communicate the implications of tests to patients and make the
meaning of the results clear and definitive to the patient. Some of the variation from this factor
may be shared with knowledge. Providers must first have the knowledge of the specific
genotype or have confidence in their ability to utilize tools such as databases and drug labeling to
make determinations about genetic factors and how they relate to their patients drug response.
The notion that their ability to explain these factors to patients is tied to knowledge was
supported by the qualitative responses that were provided in this dissertation study. The
qualitative responses in this dissertation study included language such as “Complex information
would need to be communicated in a short amount of time” and “The population I work with has
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many health literacy challenges even with more basic concepts”. These support the notion that
some providers have concerns about the complexity of the information, the comprehension levels
of different patients and the amount of time available for providers to discuss complex
information with patients in the clinical setting. When questioned about their perception of
providers ability to explain information about pharmacogenomics testing to patients, responses in
this dissertation study included “lack of education about the testing” and “Teaching or education
is required”, which suggest that additional training and support on the communication of
pharmacogenomics test implications are desired by provides in the clinic, but not readily
available. Additionally, comments such as “understanding pharmacology is difficult for mid
levels”, indicate that there is a differential among provider types in the level of knowledge and
self-efficacy to effectively explain pharmacogenomics tests to patients.
Need for in-clinic training
This study showed a need for additional training and support within the clinical setting.
Responses to study questions indicated a need for on the job experience and observation.
Additionally, qualitative feedback suggested that while many providers were interested in
learning more about pharmacogenomics, training opportunities were not available in their
settings. This may relate to the concept of trialability in Rogers theory (Roger, 2010). Possibly,
individuals desire on-the-job opportunities to work with pharmacogenomics in their setting on a
test basis to experience and observe the practices and make further determinations about the
technology as well as validate assumptions that they may have about it. These findings were in
agreement with similar, recently conducted studies. A 2015 study by Unertl found that, based on
analysis of interview data, three high-level theme categories existed. The themes were
preparation and knowledge, pharmacogenomics usage in practice, and future implementation
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challenges (Unertl, Field, Price, & Peterson, 2015). The findings from this study support the
notion that additional training and support on-the-job are necessary to improve adoption.
Compatibility in the emergent setting
One of the themes in the qualitative data also suggested that Urgent Care and Emergency
providers perceived that pharmacogenomic testing was not compatible with the Emergent
setting. Comments such as, “doubtful this would be useful in urgent care as we don't usually do
send out tests that require follow up” and “Impractical in ER setting given time line of
treatment”, suggest that providers in the emergent care setting perceive a lack of compatibility of
pharmacogenomic technology with the emergent care setting. Compatibility is a major factor in
the persuasion construct of Diffusion of Innovations theory. This suggests that in some cases,
even if attitude is otherwise positive and knowledge is sufficient this factor may be prohibitive to
adoption and could be a new factor that was not measured in this study quantitatively. To test
support for this, the likelihood of adoption was compared by therapeutic setting to see if there
was a lower probability of adoption measure by adoption composite PI-created PAI© scores in
Emergency Medicine providers when compared to all other types. Indeed, this comparison
showed an odds ratio of 1.26, meaning other providers were 1.26 times more likely to adopt than
Emergency Medicine providers. This may not include Urgent Care providers, as some Urgent
Care providers selected the other category when selecting therapeutic specialization. This result
should be interpreted with caution, as whether these two areas may be distinctly different
quantitatively was not considered in the initial design of this study tool. The post-data collection
literature search initially suggested that this may be a novel finding, as no previous literature had
discussed this topic. However, a study was then published in February 2016, which discussed
the potential role of pharmacogenomics in the Trauma setting (Samai, K., 2016). Samai’s study
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had mixed positions on the use of pharmacogenomics in the trauma setting. The paper posits
that while the potential exists for clinical benefit in the trauma setting, the setting-specific
challenges that prevent its initiation may outweigh those benefits. The study cites a potential
lack of time to properly provide informed consent to patients, as well as a high potential for
reduced capacity in patients to provide consent in this setting. Both Samai’s paper and this
dissertation study are in agreement with regard to these findings and the need to further explore
the specific barriers that exist in the Urgent/Emergency/Trauma setting, as they may differ from
those in other settings.
Refinement of the theoretical model
Based on the findings from this study, the data did not support the theoretical frame as it
was proposed. This study’s findings suggest revisions to the theoretical frame. Figure X shows
the conceptual model of study variables in context of Rogers Diffusion of Innovation Theory.
The conceptual model denotes the receiver variable characteristics, those which are inherent to
the potential adopter, in this case they included provider type, therapeutic specialization, years of
experience in their practice, adopter category, and other basic demography including age and
gender. The conceptual model highlights the fact that experience in the clinic was found to be a
qualitative concern in adoption and the only knowledge variable that significantly predicted
adoption outcomes. The conceptual model also shows that attitude variables were the most
significant predictors of outcome. Diagnostic value, increased safety, impact on quality of
healthcare, misuse of genetic data, genetic discrimination, and patient/provider ability to
understand were all found to be significant predictors of adoption outcome. Compatibility in the
Emergent setting was proposed to be a potential factor that may contribute to the adoption
process. In the persuasion domain the elements of relative advantage, compatibility, complexity,
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Figure 9.. Conceptuall model of sttudy variables. The aboove conceptuual diagram iillustrates the
componeents of Rogerrs’ Diffusion
n of Innovatiions Theoryy, as related tto the variabbles in this sttudy.
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Limitations
There were a number of limitations to this study. The first was related to the chainreferral sampling methodology. There were benefits to using this method of sampling; however
there were also drawbacks that were a result of this sampling. Namely, since this sampling
method allows invitations to be forwarded outside of the original recipients, it becomes
impossible to control the geographic dispersion or the number of participants in any given group.
This resulted in a geographic representation that was highly skewed towards 3 northeast states.
The states of NJ, NY and PA made up about 50% of all PI-created PAI© responses. Though
other geographic regions were represented to a smaller extent, the representativeness of this
study may be limited to healthcare providers in the majority states represented. Another issue
with the chain referral methodology is that there was no contact information collected for
respondents, making a follow-up or longitudinal subsequent study not possible. The Survey
Monkey link was also only provided to participants electronically via e-mail, therefore, the study
may have excluded those without access to e-mail or those.
Further, the nature of non-purposive sampling, as a whole, limits the generalizability of
the findings to the members of the sample as the population. This sample of convenience may be
inferentially informing, but places limitations on what can be deduced. Thus, while we can make
inferences about how these findings may relate to the greater population, the lack of
randomization and selective sampling limits the extent to which data from this sample can be
extrapolated to make inferences about a larger population.
Another limitation of the study is the correlational design measuring knowledge with
adoption and attitudes with adoption. Though, both of these constructs can be compared with
adoption likelihood, the use of correlational methods makes it impossible to establish causality
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between either of these factors. So, while the study can say that there is a relationship between
pharmacogenomic knowledge and adoption likelihood, and a relationship between attitude and
adoption likelihood, it cannot say that higher knowledge or positive attitude, overall, can be
causally linked to the likelihood of adoption. The findings do, however, support the greater
model predicted in regression, in the framework of Rogers Diffusion of Innovations theory.
The study tool offered limitations in measuring adoption. Since the study used the PIcreated PAI© to measure the construct of adoption likelihood, what was actually being measured
was self-reporting of likelihood to adopt. All prior studies that have investigated adoption of
pharmacogenomics have used this measure as a surrogate marker for adoption behavior, however
no study has yet looked at actual implementation rates of pharmacogenomic testing in clinical
practices among these groups and validated how closely a reported likelihood of adoption
correlates with actual follow-through.

Directions for future research
This study yielded many questions that create the basis for future scholarly inquiry. For
one, the geographical limitations of the study sample limited the generalizability of the results, as
mentioned in the study limitations. A subsequent study that geographically expands the sample
to have a more nationally representative sample, would offer much more generalizability to the
US provider population and allow much broader inferences and implications. This may be
achieved with purposive sampling. Though in a purposive sample, the recipients must be preselected and arranged to provide a representative sample from the selected centers. A purposive
sample would need to take caution in selecting the centers and invitees to ensure representative
response.
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There has been little investigation of pharmacogenomics in the Emergency Care Setting.
Further investigating the findings from the Emergency/Urgent Care setting, qualitatively in more
depth, may reveal the factors that make this different from other clinical settings. While time
was cited anecdotally in this dissertation study, it would be of benefit to investigate this factor
empirically. Literature has suggested, philosophically that the potential exists for clinical benefit
in some types of emergent settings, however it has been suggested that the specific challenges
that prevent its initiation may outweigh those benefits. The literature supports the notion of
potential time constraints to employ pharamacogenomics in the clinic, but it has not been
investigated empirically.
Finally, this study utilized a survey tool and measured likelihood of adoption through
questions that estimated a providers potential for adoption. That is, it used a cross-sectional
design, employing the PI-created PAI© tool to measure likelihood of adoption. To increase
precision and accuracy, it could be beneficial to conduct a study that looked at actual use of
pharmacogenomic technology in providers in the clinic and then retrospectively investigate
factors as compared to a control group, which is not utilizing pharmacogenomic techonolgy in
practice. Employing a case-control design may eliminate some of the confounding effects that
are encountered when measuring outcome through an endpoint that requires estimation. A study
of actual users of pharmacogenomics could eliminate additional variation that could attenuate the
effect of a predictive model.
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Chapter VI
CONCLUSION

This study investigated a number of thematic factors from the literature in a diverse group
of providers studied sided-by-side. Though, the literature identified a number of barriers that
may be prohibiting the use of pharmacogenomic technology. Only some of these factors were
shown to have an effect on adoption likelihood, in this study. This study looked at provider
types that have been studied very little, if not all. These healthcare providers, such as physician
assistants, nurse practitioners and others have a growing role in patient prescribing and decision
making. This study collected perceptions of these provider types and measured the issues that
had yet to be examined in an empirical study. Qualitatively, new themes emerged from the data
collection that implicated the basis for future research. These themes suggested that setting may
have a larger role than previous literature anticipated and the emergent setting may be
qualitatively different from other clinical settings. The themes also suggested that on-the-job
training opportunities may help to reduce barriers related to these factors, although nuances in
the quantitative data caveat that the training needs to be designed to address the appropriate
factors and address not only knowledge, but issues related to attitude and informing on
attitudinal concerns. The information gained from the conduct of this study will, hopefully, help
to inform on the issues discussed, and have an impact on the adoption of pharmacogenomic tests
in the post-genomic era and thus, greatly improve the quality and cost-effectiveness of care for
patients in this new paradigm.
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Date:

April 14, 2015

Re.:

Permission to Invite Our IHSA PhD Students to Participate in your Dissertation Study

To:

Jason Sudia

From: Terrence F. Cahill, Chair, IHSA

This is to confirm that you will have access to invite our IHSA PhD in Health Science students to
participate in your study concerning the use of pharmacogenomic testing in clinical practice. As only a
portion of our students will have the experience that you are studying and/or know someone else who
may have the experience that they can snowball the invitation to, you will need to clearly address this
matter in your solicitation, Jason.

School of Health and Medical Sciences
Department of Interprofessional Health Sciences and Health Administration
Tel 973 275 2076 Fax 973 275 2370 TDD 973 275 2169
400 South Orange Avenue South Orange, New Jersey 07079
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Dear Healthcare Provider,
My name is Jason Sudia. I am a student at the School of Health and Medical Sciences at Seton Hall
University. I am conducting this research study as part of my doctoral dissertation.

What is the purpose of the study?
You have been invited to participate in this survey study. You have been invited because you may be a
healthcare provider that works in the clinical setting. Previous research has suggested that some factors
may prevent the use of pharmacogenomic tests in the clinic. The purpose of this study is to determine
how much clinical healthcare providers understand about pharmacogenomic testing. Another purpose
is also to find whether they are using it in the clinic. Another is to find if the main reason why they may
not be using it.

What is the study procedure?
You are being asked to complete the survey if you fit the requirements. The requirements are, being a
healthcare provider that has interaction in the pharmacological treatment of patients. You may
complete the survey by clicking on the link below. This study will also be utilizing a recruitment
technique known as chain‐referral or snowball sampling. This means you are encouraged to forward
this e‐mail to anyone that you think meets the requirement of being a clinical healthcare provider. They
may then determine if they have interaction in the pharmacological treatment of patients. Anyone who
fits that requirement may participate in the study. They may then complete the study, even if you do
not. This allows the survey to reach a greater audience. Thus, it may gather more information than it
would, otherwise. The attached link is not unique to you. It may be forwarded to anyone. No record
will be kept regarding whether or not you completed the survey. Nor will a record of be kept of who
you forwarded it to. Completing the multiple choice question portion of the survey will take about 10‐
15 minutes. There is an open‐ended question. You can take as much time as you would like to complete
this.

Is participation voluntary?
Your participation in this research study is completely voluntary. You may decide not to participate at
any time. If you choose not to participate, you will not be penalized nor lose any benefits to which you
are otherwise entitled to. By clicking the link below, you acknowledge that you are providing your
consent to participate in this study.
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Is the survey anonymous?
Your identity will not be collected as part of this study. Your name, address, and other specific personal
identifying information will not be collected. The information that will be collected is general
demographic information. There will be no records identifying you, specifically. All of your answers will
be recorded anonymously. There will be no way to contact you or link your answers to you. If you
forward the survey to others, no specific identifying information will be collected from them. The
research data may be published. If it is, it will not identify any individual.

What will happen to the study data?
The study data will be kept confidential to protect its integrity. The data will be stored on a USB drive.
The USB drive will be locked in a cabinet in the office of the principal investigator. The principal
investigator, Jason Sudia, will have access to all of the data for a period of up to three years after the
end of the study. After that time, the research data will be destroyed.

Can I request further information?
If you decide that you have an interest in learning more about pharmacogenomics and its application in
the clinic please feel free to contact me at the e‐mail address below for more information. You may
send questions about the survey. You may also request the correct answers to the knowledge
questions.

Thank you for taking the time to read this and consider participating in this study.

Best Regards,

Jason Sudia
Jason.sudia@student.shu.edu
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(First page example as appears in Survey Monkey, for the full PAI© survey,
please contact the author at jason.sudia@student.shu.edu)
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Delphi Review Expert Panel Methodology and Procedures
A structured, modified Delphi procedure was performed to achieve face validity of the survey questions.
The procedure included the key elements of Delphi according to Fowles (Fowles, 1978). These include
anonymity of the panelists from one another, controlled feedback and integrated moderation and
summarization of comments and revisions, and a statistical characterization of the panelists responses
to achieve a predetermined threshold, in this case greater than eighty percent consensus in approval of
construct.
1.

Selection of the five member pharmacogenomics adoption expert panel reviewers.
A five member panel was selected based on a few factors. The first was publication of a paper
that examined the utilization of pharmacogenomic technology in the clinical setting. This was a
first criteria. The second was publication of a paper that examined this issue via survey
methodology. The third selection factor was the number of papers that met the first two
criteria and the frequency of citation of these papers as reported by EBSCO Academic databases.
The 10 leading candidates were contacted and were then asked if they were willing and
available to provide review. Seven of ten were willing and 5 were selected as panelists.

2.

Development of the first round modified Delphi questionnaire.
The author and project academic advisor, in conjunction with the doctoral committee, created a
worksheet to measure agreement with the proposed constructs in the survey questions that
were drawn from topics in the literature and other studies that had investigated some of these
issues independently or in other populations. The constructs were mapped and identified with
the question in the worksheet and the sheet asked for comments and for expert agreement or
objection with the proposed construct.

3.

Testing the questionnaire for precision and clarity with dissertation committee.
The doctoral committee then met to review the proposed worksheet and provided revisions for
clarity and precision. The revised worksheet and questions were then sent out to an expert
reviewer that was not a member if the panel to determine if any content specific issues arose
from the language revisions. The worksheet was revised and reviewed by the academic chair
and doctoral committee.

4.

Transmission of the first round questionnaires to the panelists.
The worksheet and questions were then sent out to the panelists. The panelists were instructed
to review each question and the related construct or factor associated with the question. They
were then asked to determine if the question measured the construct or factor described. They
then checked yes or no to indicate their position. Expert reviewers were instructed to provide
comments or further explanation if they indicated no. Reviewers were also instructed that they
may make suggestions or any additional comments, even if the construct was in agreement with
the question. They were instructed to return the comments for the first round of the Delphi
within seven days of receipt.
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5.

Analysis of the first round responses.
The first round responses to the Delphi worksheet were calculated and summarized. A
consensus was calculated (Appendix I). A minimum consensus of 80% agreement of the panel
was sought. Questions that did not achieve 80% consensus were modified per the Delphi
members’ feedback. The proposed revisions were reviewed and refined by the doctoral
dissertation committee.

6.

Preparation of the second round questionnaires.
Once the final revisions were reviewed and refined by the doctoral committee, the revised
questions were reformatted into a final version worksheet. The worksheet included a check box
asking if the revised question measured the intended construct indicated for the questions that
achieved below 80% consensus in the first round. The worksheet also included a comments box
for all questions and the questions that achieved greater than 80% consensus were included for
a final quality check.

7.

Transmission of the second round questionnaires to the panelists
The second round questions and worksheets were then sent to the panelists for review Expert
reviewers were instructed to provide comments or further explanation if they indicated no to
the question of construct and question agreement. Reviewers were also instructed that they
may suggest any additional comments even if the construct was in agreement with the
question. They were instructed to return the comments for the first round of the Delphi within
seven days of receipt.

8.

Analysis of the second round responses
The second round responses to the Delphi worksheet were calculated and summarized. A
consensus was calculated (Appendix I). A minimum consensus of 80% agreement of the panel
was sought. All questions achieved 80% consensus or greater in the second round, however
some feedback was given by the expert panelists on improving the clarity of the question. The
suggested clarifications were made per the Delphi members’ feedback. The proposed revisions
were reviewed and refined by the doctoral dissertation committee.

9.

Final quality control review by expert reviewers
The final revisions of the survey questions were entered into Survey Monkey for quality control
testing by an expert independent to the expert panelists. The link to the survey was sent to the
expert reviewer. The expert reviewer indicated that the survey questions were satisfactory in
structure and clarity. The link to the survey was then sent to the members of the expert panel.
The panelists indicated that the questions accurately reflected the intentions of the feedback
and revisions and were acceptable in structure and clarity.

122

© 2016 Jason Sudia

APPENDIX I
Delphi Expert Reviewer Instructions

123

Dear Expert Panelist,

Thank you for agreeing to provide your expert opinion on the Pharmacogenomic Adoption
Instrument (PAI) tool. You have been asked to provide your feedback, based on your specific expertise,
which has been identified as a subject matter that is highly relevant to the tool. Your feedback will be
used to refine and improve the questionnaire, so any insight you have will be greatly appreciated and
used for this purpose. Your input will be integrated along with the other Expert Panelists’ responses
through a Modified Delphi process to achieve face and content validity for this instrument.

The purpose of the instrument once it is reviewed and revised by the expert panelists and
distributed to survey participants is to examine healthcare providers’ knowledge of and attitudes
toward pharmacogenomics technology to help address a gap in the current literature. The survey
questions are rooted in themes that recur in the current literature that discuss pharmacogenomic
technology and its adoption by healthcare providers. The survey tool utilizes Roger’s Diffusion of
Innovation Theory (Rogers, 2010). The questions in the survey have been written to reflect themes in
the literature in the context of this theory.

Please review each question and the related construct or factor associated with the question.
You will then be asked to determine if the question measures the construct or factor described. Please
check yes or no to indicate your decision. If you have comments or questions in any of the above
categories, you may then use the comments box to elaborate your suggestion for refinement or
improvement in that specific category. Your comments for this first round of the Delphi are requested
within (7) days of receipt. The survey tool will then be modified based on the responses that were
received from the expert panel. A consensus (80% agreement) of the panel will be sought. If consensus
is not met you will be asked to participate in a second review round but only specific to those questions
not reaching consensus. For the second round you will again be asked to provide your comments within
(7) days of receipt. If consensus is not met following the second round, then a third and final round will
be conducted to reconcile these disagreements. Further instructions will be provided to you at that
time. Majority panel recommendations will be followed for each round. A majority is represented by
agreement between 80% or more of the panel.

Also, if there is/are any question(s) that you think would improve the survey that you think
might relate to or provide more insight into the adoption of pharmacogenomic technology by healthcare
providers in their practice now or in the future, but was/were not captured appropriately as written
here or not included at all but you feel should be, your suggestion(s) on what and how to include this
© 2016 Jason Sudia
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information please feel free to write the question and corresponding answer in the appropriate
section comment box.

Your anticipated support in this project is greatly appreciated!

Very Respectfully,

Jason Sudia

Doctoral student, Seton Hall School of Health and Medical Sciences
Jason.sudia@student.shu.edu

Background and Rationale
The literature has found that there are many different barriers that impede the path of
pharmacogenomic technology and its adoption by healthcare providers in the clinic. Pharmacogenomics
is the field of study that deals with understanding the differences in human genetic variation and the
effects of these differences on the safety and efficacy of pharmacological treatments. This information
and its use can greatly reduce adverse events due to drugs and greatly increase the probability of
prescribing a drug in the correct dose that will work effectively for that patient (Crews, 2012). These
barriers range from potential philosophical ethical issues to a real lack of training and awareness among
practitioners (Bonter, Desjardins, Currier, Pun, & Ashbury, 2011; Leufkens, 2004; Ventola, 2011).

Theory of Diffusion of Innovations
The Theory of Diffusion of Innovations may help to explain what factors are impeding the
translation of this advancement in the clinical setting. Roger’s 1967 Diffusion of Innovation Theory
describes the way people, as a group, adopt technology (Rogers, 2010). The theory has been applied to
many technologies that have emerged in and outside healthcare. This theory has strong applicability
and may help to explain how and why the breach exists between the science and the practice. In a
recent survey of US physicians, only 10% of those surveyed indicated that they felt sufficiently informed
about the accessibility of pharmacogenomic technology and how to appropriately utilize it to aid
diagnosis and determine the best course of therapy for patients (Stanek, Sanders, Taber 2012). In the
© 2016 Jason Sudia
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process of adoption of new technology there are key components that catalyze the process. Of these,
are the initial attitudes and knowledge of the potential adopters (Rogers, 2010). When knowledge is
insufficient or attitudes toward the technology are unfavorable adoption of the technology is halted.
Purpose
The purpose of the research that this tool will be used to conduct is multiple. First, the research
will aim to determine, which factors are most strongly related to resistance in the adoption of
pharmacogenomic technology by healthcare providers in the clinic? The literature and current theory on
technology adoption in healthcare provides a background that suggests that a relationship may exist
between knowledge of pharmacogenomic testing and the likelihood of adoption. Therefore
pharmacogenomic knowledge will be assessed as a primary measure of this tool. The literature and
current theory on technology adoption in healthcare also provides a strong case that suggests that a
relationship may also exist between attitudes toward pharmacogenomic testing and the likelihood of
adoption. Thus, attitudes toward pharmacogenomics will also be a primary measure of this tool. The
survey instrument below is based on the constructs and evidence found in a number of previous studies.
This survey tool has no previous, demonstrated, history of reliability or validity. Thus requiring some
level of validation before it can be implemented and tested in a healthcare provider population.

Questions
The following survey consists of 40 questions. The construct questions will utilize a two digit score. A
score value of 100 on a single question indicates uncertainty about that topic or question. The hundreds
value will be considered for this purpose. Questions that appeared in multiple studies in the literature
were selected to represent some constructs of interest. Other questions were developed using concepts
from the literature to address gaps that have not been previously investigated. The overall scoring of
the questions will be analyzed according to the following guidelines:
Demography
Questions 1, 4, 5, 7, 36, 38, and 39 aim to characterize the demography and attributes of the sample.
This data will be descriptive in nature and will provide a depiction of the distribution of factors that this
sample represents. These questions also aim to capture the frequency of factors that were described in
the literature regarding pharmacogenomic adoption.
Qualitative Barriers
Questions 2 and 3 aim to identify the primary barriers to the adoption of pharmacogenomic technology
in the clinical setting.
Scores will be a composite of hundreds value and a two digit number (e.g. 999) the two digit number are
interpreted as follows:
© 2016 Jason Sudia
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Attitudes
Questions 6, 24, 25, 26, 27, 28, 29, 30, 31 aim to measure attitudes of subjects toward
pharmacogenomic technology. The range of scores in this category is 9‐45. A lower score indicates a
more unfavorable attitude towards pharmacogenomic technology, while a higher score represents a
more favorable attitude towards pharmacogenomics technology.
Experience
Questions 8, 10, 12, 14, 15 and 16 aim to measure experience with pharmacogenomic techonology in
the clinic. The range of scores in this category is 6‐30. A lower score indicates a less experience with
pharmacogenomic technology, while a higher score represents more experience with
pharmacogenomics technology.
Knowledge
Questions 9, 11, 13, 17, 18, 19, 20, 21, 22, 23 and 32 aim to measure knowledge of pharmacogenomic
technology. The range of scores in this category is 11‐55. A lower score indicates a less knowledge of
pharmacogenomic technology, while a higher score represents greater knowledge of pharmacogenomic
technology.
Likelihood of Adoption
Questions 33, 34, 35 and 37 aim to measure likelihood of adoption of pharmacogenomic technology in
the clinic. The range of scores in this category is 3‐20. A lower score indicates a lower likelihood of
adopting pharmacogenomic technology in clinical practice, while a higher score represents greater
likelihood of adopting pharmacogenomic technology in clinical practice.
Uncertainty
In the event a participant selects a “do not know” answer a score of 100 will be assigned. Scores of 100
on a response, indicate uncertainty in making a decision. Thus the hundreds value of the total score is
considered separately from the two‐digit value, which indicates a definitive response. A high hundreds
value score indicates high uncertainty and likely unfamiliarity with pharmacogenomics technology.
Scores indicated in survey below in (red).
The scoring of the responses will not be disclosed to the survey participants, but are indicated in red (x)
to demonstrate the scoring scheme of the survey for this review.
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